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Background & Aims: The guidelines of the European Society of Pediatric Gastroenterology, 
Hepatology, and Nutrition allow for diagnosis of celiac disease without biopsies in children 
with symptoms and levels of immunoglobulin A against tissue-transglutaminase (TGA-IgA) 
10-fold or more the upper limit of normal (ULN), confirmed by detection of endomysium 
antibodies (EMA) and positivity for HLA-DQ2/DQ8. We performed a large, international 
prospective study to validate this approach. 
Methods: We collected data from consecutive pediatric patients (18 years or younger) on a 
gluten-containing diet who tested positive for TGA-IgA from November 2011 through May 
2014, seen at 33 pediatric gastroenterology units in 21 countries. Local centers recorded 
symptoms; measurements of total IgA, TGA, and EMA; and histopathology findings from 
duodenal biopsies. Children were considered to have malabsorption if they had chronic 
diarrhea, weight loss (or insufficient gain), growth failure, or anemia. We directly compared 
central findings from 16 antibody tests (8 for TGA-IgA, 1 for TGA-IgG, 6 for IgG against 
deamidated gliadin peptides, and 1 for EMA, from 5 different manufacturers) 2 HLA-
DQ2/DQ8 tests from 2 manufacturers, and histopathology findings from the reference 
pathologist. Final diagnoses were based on local and central results. If all local and central 
results were concordant for celiac disease, cases were classified as proven celiac disease. 
Patients with only a low level of TGA-IgA (3-fold or less below the ULN) but no other results 
indicating celiac disease were classified as no celiac disease. Central histo-morphometry 
analyses were performed on all other biopsies and cases were carefully reviewed in a blinded 
manner. Inconclusive cases were regarded as not having celiac disease for calculation of 
diagnostic accuracy. The primary aim was to determine whether the non-biopsy approach 
identifies children with celiac disease with a positive predictive value (PPV) above 99% in 
clinical practice. Secondary aims included comparing performance of different serological 
tests and to determine whether the suggested criteria can be simplified. 
 
Results: Of 803 children recruited for the study, 96 were excluded due to incomplete data, 
low level of IgA, or poor-quality biopsies. In the remaining 707 children (65.1% girls; median 
age, 6.2 years) 645 were diagnosed with celiac disease, 46 were found not to have celiac 
disease, and 16 had inconclusive results. Findings from local laboratories of TGA-IgA 10-fold 
or more the ULN, a positive result from the test for EMA, and any symptom identified 
children with celiac disease (n=399) with a PPV of 99.75 (95% CI, 98.61–99.99); the PPV 
was 100.00 (95% CI, 98.68–100.00) when only malabsorption symptoms were used instead of 
any symptom (n=278). Inclusion of HLA analyses did not increase accuracy. Findings from 
central laboratories differed greatly for patients with lower levels of antibodies, but when 
levels of TGA-IgA were 10-fold or more the ULN, PPVs ranged from 99.63 (95% CI, 98.67–
99.96) to 100.00 (95% CI, 99.23–100.00). 
 
Conclusions: Children can be accurately diagnosed with celiac disease without biopsy 
analysis. Diagnosis based on level of TGA-IgA 10-fold or more the ULN, a positive result 
from the EMA tests in a second blood sample, and the presence of at least 1 symptom could 
avoid risks and costs of endoscopy for more than half the children with celiac disease 
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worldwide. HLA analysis is not required for accurate diagnosis. Clinical Trial Registration 
no: DRKS00003555 
 
KEY WORDS: ESPGHAN; non-biopsy approach; autoimmunity; ProCeDE study  
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Introduction: 
Celiac disease (CD) is an autoimmune disorder triggered by gluten and related prolamines in 
genetically susceptible individuals carrying the HLA-DQ2 and/or -DQ8 alleles
1
. CD is characterized by 
enteropathy and presence of CD-specific autoantibodies against tissue-transglutaminase 
(transglutaminase type 2, TGA) and endomysium (EMA). The prevalence of CD in Europe and North-
America is about 1-2%
2
, with higher rates in first-degree relatives of CD patients and individuals with 
associated disorders such as type 1 diabetes mellitus or trisomy 21
3
.  
Until 2012 the histological proof of villous atrophy on small bowel biopsies was obligatory for the 
diagnosis of CD. During the last decade unambiguousness of histopathology was questioned
4-6
, while 
a strong correlation between TGA titer levels and severity of mucosal lesions was recognized
7
.  
In 2012 the European Society of Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) 
published new diagnostic criteria for CD
1
.  
These criteria gave pediatric gastroenterologists the option to diagnose CD without biopsies in 
children with symptoms indicative for CD, serum TGA-IgA titers above 10 times upper limit of normal 
(≥10xULN) in a calibration-curve-based test, positive EMA-IgA in a second blood sample and positive 
HLA-risk alleles. The evidence for this approach was mostly based on retrospective data or small 
single-center studies.  
Our Prospective Celiac Disease Diagnostic Evaluation study (ProCeDE) aimed to evaluate in a multi-
center setting whether this non-biopsy approach allows a correct diagnosis in clinical practice with a 
positive predictive value above 99% when all required conditions are fulfilled.  
Secondary aims included determining the accuracies of various TGA-tests and their reliability to 
predict CD if levels are ≥10xULN as well as the impact of HLA-typing, EMA-IgA, and type of symptoms 
on CD diagnosis without biopsies.  
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Methods:  
Study design and participants:  
From November 2011 to May 2014, 33 pediatric gastroenterology units from 21 countries (Europe, 
Middle East) recruited consecutive patients <19 years on a gluten-containing diet, with positive TGA 
results analyzed in their own or external laboratories. Exclusion criteria comprised refusal to 
duodenal biopsies, primary or secondary immunodeficiency, malignancy or previous diagnosis of CD. 
Recruited patients were excluded from the analysis if local and central HLA-results were unavailable, 
serum or histology slides were not provided for central assessment, biopsies were unreadable due to 
poor quality, total IgA was low, inclusion criteria were violated or consent was withdrawn.  
Local work up 
Obligatory diagnostic work-up at the local site included serology (total IgA, TGA, EMA) and 
histopathology from duodenal biopsies. Collected data comprised family, medical and dietary history, 
symptoms, physical examination, basic laboratory parameters, most recent local TGA- and EMA-IgA 
results including date of measurement and name of test-kit/manufacturer with respective upper 
limit of normal (ULN) (supplementary tables S1, S2), local HLA-typing for DQ2/DQ8 if performed, 
endoscopy findings, histopathology including Marsh-Oberhuber staging
8,9
 and local diagnosis (CD, no 
CD, unclear). Data entry was completed into study database before central analysis started. Local 
serology should have been done maximum two weeks prior to or at biopsy. Serum for central 
laboratory, DNA, and histology slides were collected at time of biopsy.  
A child was considered to have low/deficient total IgA if serum concentration was <0.25 g/l, negative 
TGA-IgA but positive IgG-based antibodies (see supplement 1.8). 
According to clinical presentation patients were stratified in three groups: malabsorption symptoms, 
other clinical symptoms and no symptoms.  
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Malabsorption was considered with at least one of the following symptoms: chronic diarrhea, weight 
loss or insufficient gain, growth failure and anemia (hemoglobin below reference value for age and 
sex). 
Central analyses 
All investigators performing central analyses were blinded towards available local and central results. 
Overall 16 antibody tests (eight TGA-IgA, one TGA-IgG, 6 DGP-IgG, and one EMA) from five different 
manufacturers were analyzed head-to-head (supplementary 1.5.2, tables S3, S4). Details and results 
on DGP-IgG tests are shown in the supplementary tables only.  
Immunofluorescent analysis of EMA-IgA was performed by one experienced technician (G.H.) with 
serum dilutions of 1:5, 1:10, 1:100, 1:1000, and 1:2.5 if 1:5 dilution was negative. A signal in 1:2.5 
dilution or higher was considered positive (supplementary 1.5.1).  
All tests were performed according to manufacturers’ instructions in a single run either on 
automated, calibrated ELISA systems (EUROIMMUN Analyzer I) or on the respective automatized 
systems (Phadia250, Thermo Fisher; QuantaFlash, INOVA). Standard curves were available for all 
tests. Two different HLA-DQ2/DQ8-typing approaches were applied (supplementary 1.6) and results 
stratified in five HLA risk groups
10,11
. Negative HLA-status was defined if none of the CD related risk 
alleles or only alleles encoding the α-subunit (without the corresponding β-subunit) of DQ2 and/or 
DQ8 were present
12
. In patients with negative HLA status but positive central serology and 
histopathology, a 3
rd
 HLA-typing for rare risk alleles was performed from a new blood sample. If 
central HLA-typing was not possible for ethical or technical reasons, local results were used.  
The reference pathologist reported histology on provided slides (hematoxylin-eosin and CD3+ 
immunostaining) including Marsh-Oberhuber-staging
8,9
. Unclear cases were blindly reviewed by a 2
nd
 
reference pathologist. If specimens were non-evaluable the paraffin embedded biopsy blocks were 
requested for reoriented cuttings and blindly evaluated including morphometry. 
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Central diagnosis 
The final central diagnosis for each patient was 1) proven CD or 2) no CD or 3) inconclusive case. CD 
was proven if HLA-DQ2/DQ8, local TGA-IgA, local and/or central EMA-IgA were all positive, and both, 
local and reference pathologists reported at least Marsh 2 staging.  
CD was excluded if HLA-DQ2/DQ8 was negative, local TGA-IgA below 3xULN, local and central EMA-
IgA were negative and local and central pathologists reported Marsh 0 or 1.  
Patients not meeting these criteria were initially considered as unclear and histopathology was 
revised as described above. The diagnostic committee reviewed each unclear case and voted in a 
Delphi process (supplementary methods 1.9, figure S2.). If this did not allow a clear diagnosis, cases 
were finally regarded as inconclusive.  
Criteria for CD diagnosis without biopsies 
For local and central TGA levels the multiple of the respective upper limit of normal (ULN) was 
calculated and stratified into high positive (≥10xULN) or low to moderate positive (>1 to <10xULN). 
For tests with a given grey zone the lower bound was used as ULN. To evaluate whether the non-
biopsy approach would contradict the final central diagnosis, we considered the combination of high 
local TGA, positive local EMA-IgA, positive central HLA-status, and symptoms. Furthermore, the 
diagnostic accuracies of high central TGA (≥10xULN) for each included commercial kit alone and in 
combinations with HLA-status, EMA results and symptoms were calculated against the central 
diagnosis as reference. 
Study oversight 
The study was approved by the ethics committees of each participating center. Written informed 
consent was obtained by legal guardians and patients as appropriate for age. The study was co-
funded by industry (EUROIMMUN Medizinische Labordiagnostika AG, Eurospital, INOVA Diagnostics, 
R-Biopharm, Phadia/Thermo-Fisher, Dr. Schär GmbH) and non-profit organizations (ESPGHAN, AOK 
Bayern health insurance, Celiac Disease patient organizations from Denmark, Finland, Germany, 
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Hungary, Italy, The Netherlands and The United Kingdom). Funding partners were not involved in 
study design, recruitment, data collection, analysis and interpretation or writing of the manuscript.  
All authors had access to the study data and reviewed and approved the final manuscript. ProCeDE is 
registered at the German Registry for Clinical Trials, Reg-No DRKS00003555. 
 
Statistical analyses 
With 701 participants the study had 80% power at 5% significance level to detect a PPV of more than 
97% for most test scenarios. Assuming an estimated ratio (PPV) ≥99% and using the exact binomial 
distribution a sample size of 348 with power of 86.1% was calculated.  
When sequential test design was considered (by ADDPlan Software, Cologne, Germany), the needed 
number increased to 357. The interim analysis with the first 200 patients showed that the proportion 
of cases potentially qualifying for omitting biopsies with local parameter ranged between 50-65%. 
Therefore we planned to recruit a minimum of 700 patients. 
Mean and standard deviation (SD) or median and range and frequency in % were indicated.  
For main analysis of diagnostic accuracies, all inconclusive cases were considered as no CD, or were 
excluded in a subsample analysis.  
Sensitivity, specificity, PPVs and positive likelihood ratios for different scenarios (TGA ≥10xULN alone 
and in combination with other criteria) were calculated with 95% confidence intervals (CI) using 
binominal distribution (Copper-Pearson CI). Sensitivity expresses the proportion of patients 
qualifying for the non-biopsy approach.  
All statistical analyses were done by B.F. and K.W. using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). 
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Results:  
Of 968 eligible patients 803 (83.0%) were recruited. Ninety-six patients were excluded, thereof 36 
due to non-evaluable histology and 17 due to low total IgA (figure 1, supplementary tables S5, S6, 
S7). From one center, all 12 patients had to be excluded due to incomplete sample sets. In the final 
cohort (N=707), 399 patients (56.4%) qualified for the non-biopsy approach according to ESPGHAN-
guidelines. Basic characteristics are shown in table 1.  
In 29 patients, local TGA-IgA was negative at time of biopsy but all had positive TGA-IgA before 
referral (supplementary table S8). Local EMA-IgA was available in 681 and central EMA-IgA in 704 
patients. Forty-five patients (7.6%) were biopsied with capsule. In those undergoing endoscopy 
macroscopic findings were reported on a standardized questionnaire in 653 patients. Erosive 
esophagitis was present in 3.7%, but no case of eosinophilic esophagitis was reported. Gastric 
erosions were found in 3.2%, duodenal erosions in 6.3% and a duodenal ulcer in 0.3% of the patients. 
Helicobacter pylori status was available in 441 patients, thereof 21 (4.5%) were positive. The local 
pathologist provided Marsh classification in 676 cases. Compared to the central pathologist there 
was disagreement regarding the histological judgement of CD (Marsh 2 or 3) and no CD (Marsh 0 or 
1) in 48/676 patients (7.1%) (supplementary table S19, S20). EurGenRisk-typing for HLA-DQ2/DQ8 
was successful in 697 and EuroArray-typing in 696/698 DNA samples. For the other nine patients 
without central DNA sample, local HLA-typing was available and considered for analysis. In total, 
18/707 patients were HLADQ2/DQ8 negative. For 2/18 patients with high suspicion of CD, the 3
rd
 
typing with new DNA material was HLAD2/DQ8-positive; the remaining 16 patients had no CD 
(supplementary table S9). 
Central diagnosis in the final cohort (N=707) was proven CD in 645 (91.2%), no CD in 46 (6.5%) and 
inconclusive case in 16 (2.3%) patients (supplementary table S10).  
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Sixty-four patients had tentatively started a gluten-free diet before the diagnostic work-up of CD, 
thereof 32 within 12 months prior to biopsy. All of them had a clear diagnosis of CD. None of the 
inconclusive patients had been on gluten-free diet before.  
Diagnostic accuracy in clinical practice 
Using the central diagnosis as reference, the diagnostic accuracies of local TGA-IgA ≥10xULN in 
combination with other criteria (scenarios) are shown in table 2. Considering all 16 inconclusive cases 
as no CD, high local TGA-IgA as single criterion (scenario 1) revealed four false positive patients 
(0.56%), thereof 2 had T1DM. If EMA-IgA was included (scenario 4), two false positive patients 
remained (0.28%). HLA-results did not improve accuracies (scenario 4).  
If all ESPGHAN criteria for the non-biopsy approach were fulfilled (table 2, scenario 5, 56.4% of the 
cohort) one patient with unspecific symptoms remained false positive. If only malabsorption 
symptoms would qualify (39.3% of the patients, scenario 6), the PPV increased to 100%.  
In the subsample analysis excluding 16 inconclusive cases, one patient was false positive for TGA 
≥10xULN (scenario 7 and 8). If malabsorption and/or EMA-IgA were included in the diagnostic 
decision no false positives were found (scenario 9-12). 
Details on false positive patients are summarized in supplementary table S11.  
Diagnostic accuracy of central serology evaluations 
PPVs for each central TGA result ≥10xULN (N=696 to 707) ranged between 99.63 [98.67; 99.96] and 
100.00 [99.23; 100.00] (figure 2). The prevalence of high TGA results varied between 22.64 [19.46; 
26.06] and 83.57 [80.48; 86.34] (supplementary table S12). Tests T4 and T6 did not reach a PPV of 
≥99% for the lower bound of the 95% CI due to respectively one and two additional false positive 
patients, thereof one child with T1DM. If malabsorption symptoms were considered for the decision, 
or if inconclusive cases were excluded, no false positive was found.  
For the DGP-IgGs ≥10xULN the specificity was high (one false positive) but sensitivity was low, for 
details see supplementary table S13, figure S3.  
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Discussion: 
The results of our prospective multi-center diagnostic evaluation study ProCeDE show that the 
ESPGHAN non-biopsy approach allows a correct diagnosis of CD. At least 50% of affected children in 
clinical practice will benefit from this non-biopsy approach which reduces burden and risks of 
endoscopy and anesthesia while saving costs for health care systems
13
. This ensuring conclusion was 
achieved in spite of using local results of a large variety of different TGA and EMA tests, which were 
performed in many laboratories in very different settings and countries. 
Since the publication of the current ESPGHAN-guidelines, several studies investigated if CD can be 
correctly diagnosed without biopsies, both in children and adults
7,13-29
. The majority were of 
retrospective nature, done by single centers, applied only one or few TGA tests and used 
histopathology as only reference standard for diagnosis. These studies had a high risk of selection 
bias excluding inconclusive cases and not acknowledging the limited inter-pathology agreement
4-6,30
. 
Our finding with discordance regarding CD diagnosis between local and central pathologists 
questions histopathology as reference standard in validation studies and supports our approach to 
build the reference diagnosis on concordant results of different diagnostic tests. There are concerns 
regarding the concept of using the same threshold (10xULN) of non-standardized tests with 
recognized inter- and intra-test variability as criterion to omit biopsies for CD diagnosis
31
. As this 
approach gives quantification of TGA concentrations a large weight, type and quality of serology tests 
are crucial and calibration curves allowing linear calculation of results are obligatory
1
. In the 
ProCeDE-study nine different TGA tests were centrally used, seven of them reliably predicted CD with 
a PPV of 100% with titers ≥10xULN and at even lower levels. This raises the question to further lower 
the threshold. However, the central lab had one standardized system following all manufacturers’ 
instructions, using the same calibration curves on automatized machines with fixed settings, 
involving the same lab technicians. In practice, inter-lab variability is high
15,32
 which we confirmed 
when comparing central and local results of the same manufacturer (supplementary fig S6, table 
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S15). In our study 10 different TGA-IgA-tests were used by the local laboratories of the 32 centers, 
with only four patients with high TGA-IgA levels ≥10xULN being false positive. This strongly supports 
that the current ESPGHAN criteria are robust in clinical practice. However, accounting for the inter- 
and intra-lab variabilities and the lack of standardization among TGA-IgA-tests and laboratories
15
, we 
recommend against lowering this threshold and keeping the 10xULN as one criterion for the non-
biopsy approach.   
Our data revealed that HLA-typing for DQ2/DQ8 does not improve accuracy of CD diagnosis without 
biopsies and can be omitted for this purpose. All patients with TGA-IgA ≥10xULN and positive EMA 
carried HLA risk alleles. Only two of 645 CD patients had initially a negative HLA-status, both were 
later reliably identified as having initially false negative HLA-results. Inter-test agreement was close 
to perfect between the two HLA tests used (supplementary S16). Negative results for HLA DQ2/DQ8 
in patients with TGA or EMA positivity are most likely false negative caused by mixing up blood 
samples or due to very rare risk allele combinations not recognized by the test systems
1,33,34
. 
A positive EMA result as obligatory criterion for the non-biopsy approach is still debated. EMA is 
more specific than TGA and DGP testing
35
, but immunofluorescence requires an experienced 
examiner
36
. As expected, sensitivity (proportion of patients qualifying for the non-biopsy approach) 
varied between participating centers. In concordance with previous studies
18,19,21,37
 inclusion of EMA 
improved the positive LR and the PPV. Our results support the use of EMA as confirmatory test when 
CD is diagnosed without biopsies.  
The ESPGHAN criteria also request the presence of symptoms for the non-biopsy approach. 
Symptoms of malabsorption increase the pre-test probability for CD compared to less specific 
complains such as abdominal pain and thereof the post-test probability of a given serological result. 
This is indicated by a higher PPV and positive LR as shown in the scenarios 1, 2 and 3 (table 2)
16,17,21,23
. 
Transient TGA-IgA positivity occurs in persons at genetic risk for CD, particularly those with T1DM
38
, 
although TGA-IgA levels are mostly low. False positive moderate or even high titer levels are more 
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likely when serologic tests with a steeper calibration curve are applied (T4 and T6 in the central lab). 
A recent population based screening study in Swedish schoolchildren suggested that the non-biopsy 
approach is also safe to diagnose CD in the absence of symptoms
24
. The number of 80 asymptomatic 
children in our study, particularly those with T1DM, was too low to draw valid conclusions.  
There is some concern that the non-biopsy approach may result in clinically relevant missed co-
morbidities such as gastroesophageal reflux disease, eosinophilic esophagitis or Helicobacter pylori 
infection related complications 
39
. However, our data suggest that the frequency of pathologic 
findings unrelated to untreated celiac disease is rare and most likely not higher than in the general 
population (supplementary manuscript).  
The main strength of our study is the large prospective cohort recruited in a variety of clinical centers 
from different countries and settings, which truly reflects clinical practice. Further advantages 
comprise detailed assessment of medical history and clinical symptoms, the large panel of local and 
central laboratory tests including central EMA-IgA, two HLA-typing tests, and central reference 
pathology. In contrast to previous studies we did not rely on local histopathology as “gold standard”, 
we based the diagnosis on concordant diagnostic test results and implemented a careful work-up 
and review process of initially unclear cases including re-cuttings and a blinded morphometric 
analysis. Our study showed the complexity and pitfalls occurring in the diagnostic work-up of children 
with suspected CD. We considered inconclusive cases as a separate group to transparently reflect 
that a clear diagnosis or exclusion of CD is not always possible. 
As a limitation, not all eligible patients were recruited, the majority due to general concerns towards 
study participation (n=81). Eleven patients with initially positive TGA-IgA in external laboratories 
were re-tested for TGA-IgA before considering endoscopy and not confirmed to have autoimmunity 
and therefore not included. In only 22 patients the reason for not being recruited was refusal 
towards biopsy, which may bear a risk for bias but does overall minimally influence the proportion of 
children qualifying for the non-biopsy approach. Furthermore, some recruited children were 
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excluded due to missing samples or data (n=24) or insufficient quality of histology specimen (n=36). 
Re-evaluation of initially inconclusive cases was only possible when paraffin blocks were available. As 
the main reasons for non-recruiting or excluding patients seem to be random and independent from 
our main outcome, we consider a low risk for selection bias within our cohort.  
We conclude from our results that the new ESPGHAN diagnostic criteria allowing omission of 
biopsies enables a correct diagnosis of CD in symptomatic children if TGA-IgA levels exceed 10xULN 
and positive EMA-IgA confirms celiac disease autoimmunity in a second blood sample. If one of these 
criteria is not fulfilled, biopsy should be performed to confirm the diagnosis. HLA-typing for DQ2/DQ8 
does not contribute to the accuracy of this two-step approach and therefore is not necessary in these 
children. 
 
 
Figure 1: Flow-chart of eligible, recruited and excluded patients and central diagnosis of final cohort 
(N=707); for the non-biopsy approach local serology results have been considered; in total 96 patients 
had been excluded, thereof 36 due to non-evaluable histopathology and 60 due to other reasons 
 
Figure 2: Positive predictive value (PPV) with 95% confidence interval (grey shaded) for CD diagnosis 
for each central TGA-serology, including eight TGA-IgA tests (T1 to T8) and one TGA-IgG test (T9), all 
with calibration curve based result calculations. The x-axis shows the multiple of the respective limit 
of normal according to the manufacturers‘ instructions (all truncated at 10xULN), the y-axis shows 
the PPV. Please see table 3 for the names and manufacturer of each test.  
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Table 1: General characteristics of the final cohort (N=707), frequencies in %, age [yrs] in median (minimum; 
maximum); stratified in three groups according to clinical manifestation: patients with malabsorption 
symptoms
#
, other clinical signs and symptoms* or no symptoms; 
Basic characteristics 
Patients by clinical manifestation Total 
Malabsorption 
symptom(s)
#
 
N=384-405& 
Other 
symptom(s)* 
N=208-222& 
No 
symptoms 
N=76-80& 
N  
Age [yrs] median (min;max) 5.0 (0.7;18.0) 7.6 (1.1;18.5) 8.4 (2.4;18.6) 707 6.2 (0.7;18.6)  
Female [%] 61.2 72.1 65.0 707 65.1 
Risk factors of CD    N % 
1st degree relative [%] 13.0 14.5 53.2 693 18.0 
2nd degree relative [%] 7.6 11.1 9.2 668 8.8 
Type 1 Diabetes mellitus [%] 4.7 12.6 22.5 705 9.2 
Autoimmune Thyroiditis [%] 1.3 4.2 2.5 690 2.3 
Down Syndrome [%] 1.5 0.0 2.5 705 1.1 
Turner Syndrome [%] 0.0 0.4 1.3 707 0.3 
Gluten consumption    N % 
Daily [%] 95.2 92.3 94.9 677 94.2 
≥ 3 to 4 times / week [%] 4.1 6.8 3.8 677 4.9 
1 to 2 times / week [%] 0.8 1.0 1.3 677 0.9 
Basic laboratory parameters    N % 
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ACCEPTED MANUSCRIPTHemoglobin < reference for age [%]  28.6 0.0 0.0 686 16.5 
Albumin < reference for age [%] 10.0 5.8 2.0 531 7.9 
ALT > reference for age [%] 9.8 5.5 7.0 613 8.2 
TPO > reference for age [%] 12.0 13.4 5.6 160 11.9 
HLA-risk group‡§    n % 
1 32.4 23.4 27.5 205 29.0 
2  8.6 10.4 2.5 60 8.5 
3 44.2 45.9 42.5 315 44.5 
4  6.2 4.1 6.3 39 5.5 
5$ 8.6 16.2 21.2 88 12.5 
# 
malabsorption symptoms: diarrhea, weight loss or insufficient weight gain, growth failure, iron deficiency anemia 
* other clinical signs and symptoms: abdominal pain, constipation, abdominal distention, flatulence, vomiting, anorexia, fatigue, 
irritability/moodiness, lack of concentration, and in children >12 yrs: delayed puberty, amenorrhea 
&
 N of patients for whom data are available vary between the different listed characteristics 
‡
 HLA risk groups were defined as follows: group 1 is associated with the lowest risk and included DR3–DQ2/DR3–DQ2 (DQ2.5/DQ2.5) 
and DR3–DQ2/DR7–DQ2 (DQ2.5/DQ2.2); group 2 DR7–DQ2/DR5–DQ7 (DQ2.2/DQ7); group 3 DR3–DQ2/DR5–DQ7 (DQ2.5/DQ7), DR3–
DQ2/DR4–DQ8 (DQ2.5/DQ8), and DR3–DQ2/other (DQ2.5/other); group 4 DR7–DQ2/DR7–DQ2 (DQ2.2/DQ2.2), DR7–DQ2/DR4–DQ8 
(DQ2.2/DQ8), and DR4–DQ8/DR4–DQ8 (DQ8/DQ8); and group 5 which is associated with a very low or no risk for CD includes DR7–
DQ2/other (DQ2.2/other), DR4–DQ8/DR5–DQ7 (DQ8/DQ7),and DR4–DQ8/other (DQ8/other); “other” refers to any HLA-DQ haplotype 
except DR3–DQ2, DR7–DQ2, DR4–DQ8,or DR5–DQ7. F 
§
 based on results from Eu-Gen-typing (Eurospital) for 697 patients, on EUROarray (Euroimmun) for one patient and for local HLA typing 
results for nine patients 
$ 
thereof in 16 patients none of the CD related risk alleles or only alleles encoding the α-subunit (without the corresponding β-subunit) of 
DQ2 and/or DQ8 were present and were therefore regarded as HLA-DQ2/DQ8 negative 
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Table 2: Diagnostic accuracies with 95% CIs to diagnose CD based on local TGA-IgA tests in combination with other criteria, either considering inconclusive 
cases as no CD (scenario 1-6, N=707) or excluding inconclusive cases (scenario 7-12, N=691); scenario 5 and 11 correspond to the current ESPGHAN criteria 
for the non-biopsy approach; TP=true positive, FP=false positive, FN=false negative, TN=true negative, PPV=positive predictive value, LR+=positive 
likelihood ratio 
Scenario N Combination TP FP FN TN Sensitivity° [95%CI] Specificity [95%CI] PPV [95%CI] LR+ [95%CI] 
1 707 Local TGA≥10xULN  458 4 187 58 71.01 [67.34; 74.48] 93.548 [84.30; 98.21] 99.134 [97.80; 99.76] 11.01 [4.26; 28.43] 
2 707 + any symptom(s) 408 3 237 59 63.26 [59.40; 66.99] 95.161 [86.50; 98.99] 99.270 [97.88; 99.85] 13.07 [4.33; 39.49] 
3 707 + malabsorption# 286 1 359 61 44.34 [40.46; 48.27] 98.387 [91.34; 99.96] 99.652 [98.07; 99.99] 27.49 [3.93; 192.50] 
4 707 
Local TGA≥10xULN  
+ EMA* (+/- HLA§) 
447 2 198 60 69.30 [65.58; 72.84] 96.774 [88.83; 99.61] 99.555 [98.40; 99.95] 21.48 [5.49; 84.07] 
5 707 + any symptom(s) 398 1 247 61 61.71 [57.83; 65.47] 98.387 [91.34; 99.96] 99.749 [98.61; 99.99] 38.26 [5.47; 267.60] 
6 707 + malabsorption# 278 0 367 62 43.10 [39.24; 47.02] 100.0 [94.22; 100.00] 100.00 [98.68; 100.00] ∞ 
  
Excluding all inconclusive cases 
7 691 Local TGA≥10xULN  458 1 187 45 71.01 [67.34; 74.48] 97.826 [88.47; 99.95] 99.782 [98.79; 99.99] 32.66 [4.70; 227.10] 
8 691 + any symptom(s) 408 1 237 45 63.26 [59.40; 66.99] 97.826 [88.47; 99.95] 99.756 [98.65; 99.99] 29.10 [4.18; 202.40] 
9 691 + malabsorption# 286 0 359 46 44.34 [40.46; 48.27] 100.00 [92.29; 100.00] 100.00 [98.72; 100.00] ∞ 
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Table 2: Diagnostic accuracies with 95% CIs to diagnose CD based on local TGA-IgA tests in combination with other criteria, either considering inconclusive 
cases as no CD (scenario 1-6, N=707) or excluding inconclusive cases (scenario 7-12, N=691); scenario 5 and 11 correspond to the current ESPGHAN criteria 
for the non-biopsy approach; TP=true positive, FP=false positive, FN=false negative, TN=true negative, PPV=positive predictive value, LR+=positive 
likelihood ratio 
Scenario N Combination TP FP FN TN Sensitivity° [95%CI] Specificity [95%CI] PPV [95%CI] LR+ [95%CI] 
10 691 
Local TGA≥10xULN  
+ EMA* (+/- HLA§) 
447 0 198 46 69.30 [65.58; 72.84] 100.00 [92.29; 100.00] 100.00 [99.18; 100.00] ∞ 
  
11 691 + any symptom(s) 398 0 247 46 61.71 [57.83; 65.47] 100.00 [92.29; 100.00] 100.00 [99.08; 100.00] ∞ 
  
12 691 + malabsorption# 278 0 367 46 43.10 [39.24; 47.02] 100.00 [92.29; 100.00] 100.00 [98.68; 100.00] ∞ 
  
°Sensitivity: proportion of patients qualifying for the non-biopsy approach 
*EMA-IgA: results of local clinical centers were considered, except for 25 patients without local EMA-IgA result for whom the central EMA-IgA was used 
§
HLA: central HLA-typing results were considered, except for nine patients with local but without central HLA-typing (eight due to ethical reasons, one due to sample 
contamination), however, including HLA outcomes had no effect on the accuracies 
# 
Malabsorption symptoms comprise any of the following: diarrhea, weight loss or insufficient weight gain, growth retardation, iron deficiency anaemia 
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Table 3: Specifications of central serology tests, including test number, name and manufacturer, type of analysis and machine, limit of normal and 
performing laboratory 
Test 
No. 
Trade name Manufacturer Type of analysis Machine 
Limit of 
normal 
Limit of 
normal 
(upper, if 
any 
range) 
Performing 
laboratory 
EMA-test 
E1 
Anti-Endomysium-IIFT IgA (or IgG) 
Tissue: monkey esophagus and liver 
EUROIMMUN 
Immunofluorescen
ce 
Fluorescence 
microscope Zeiss 
1:2.5
+
 1:5 Munich* 
TGA-tests  
T1 EliA Celikey IgA Thermo Fisher 
Fluoescence 
Enzyme 
Immunoassay 
Phadia 250 7 U/ml 10 U/ml Odense 
T2 VarelisA Celikey® tTG-IgA ELISA Thermo Fisher ELISA 
EUROIMMUN 
Analyzer I 
5 U/ml 8 U/ml Odense 
T3 QUANTA Lite tTG IgA Inova diagnostics ELISA 
EUROIMMUN 
Analyzer I 
4 U/ml 10 U/ml Odense 
T4 QUANTA Flash tTG IgA  Inova diagnostics Chemiluminescenc BioFlash 20 U 30 U Munich 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
e 
T5 Eu-tTG IgA New - code 9105 Eurospital ELISA 
EUROIMMUN 
Analyzer I 
9 U/ml 16 U/ml Odense 
T6 
Anti-Gewebstransglutaminase-ELISA 
(IgA) 
EUROIMMUN ELISA 
EUROIMMUN 
Analyzer I 
20 
RU/ml 
--- Odense 
T7 Anti-TG2-IgA (open form) 
R-
Biopharm/Zedira 
ELISA 
EUROIMMUN 
Analyzer I 
2.6 U/ml 3.5 U/ml Odense 
T8 Anti-TG2-IgA (closed form/standard) 
R-
Biopharm/Zedira 
ELISA 
EUROIMMUN 
Analyzer I 
2.6 U/ml 3.5 U/ml Odense 
T9 Anti-TG2-IgG (open form) 
R-
Biopharm/Zedira 
ELISA 
EUROIMMUN 
Analyzer I 
2.6 U/ml 3.5 U/ml Odense 
DGP-tests 
D1 EliA GliadinDP IgG Thermo Fisher 
Fluoescence 
Enzyme 
Immunoassay 
Phadia 250 7 U/ml 10 U/ml Odense 
D2 QUANTA Lite DGP IgG Inova diagnostics ELISA EUROIMMUN 20-30 U 30 U Odense 
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Analyzer I 
D3 QUANTA Flash DGP IgG Inova diagnostics 
Chemiluminescenc
e 
BioFlash 20-30 U 30 U Munich 
D4 a-Gliapep-IgG - code 9138 Eurospital ELISA 
EUROIMMUN 
Analyzer I 
10 U/ml --- Odense 
D5 Anti-Gliadin(GAF-3X)-ELISA IgG EUROIMMUN ELISA 
EUROIMMUN 
Analyzer I 
25 
RU/ml 
--- Odense 
D6 Anti-DGPx1-IgG 
R-
Biopharm/Zedira 
ELISA 
EUROIMMUN 
Analyzer I 
5.8 U/ml 8.4 U/ml Odense 
+
 1:2.5 dilutions done in patients (n=16) with negative central EMA at 1:5 due to with discrepant results or negative HLA 
*immunofluorescence evaluations were exclusively done by one experienced bioanalyst 
# only done in IgA-deficient cases or if exclusion of IgA deficiency needed to be confirmed 
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Figure 1 
968 potentially eligible patients 
from 33 centers/21 countries 
TGA-IgA initially above limit of normal 
 (respectively –IgG in case of IgA deficiency) 
803 recruited patients  
from 33 centers 
165 patients (17.0%) not included  
- refused participation n=81 
- refused biopsy n=22 
- failed inclusion/exclusion criteria n=31 
- other reasons n=31 
743 patients 
from 32 centers 
60 patients (7.5%) excluded due to  
- missing samples/specimen n=24 
- low total IgA n=17 
- withdrawal of study/biopsy consent n=12 
- violation of in/exclusion criteria n=5 
- technical error with samples n=2 
N=406 
fulfill ESPGHAN criteria 
for the non-biopsy 
approach*  
N=399 
- proven CD (n=398) 
- no CD (n=0) 
- inconclusive (n=1) 
N=337 
do not fulfill the ESPGHAN 
criteria for the non-biopsy 
approach+ 
N=7 
excluded because 
of non-evaluable 
histopathology# 
N=308 
- proven CD (n=247) 
- no CD (n=46) 
- inconclusive (n=15) 
N=29 
excluded because 
of non-evaluable 
histopathology# 
 
* 
high local TGA-IgA ≥10x ULN plus positive local EMA-IgA plus HLA plus any symptom 
+ 
low local TGA-IgA <10xULN and/or negative local EMA-IgA and/or negative HLA and/or no symptoms 
#  
non-evaluable as considered by the reference pathologist 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Werkstetter - ProCeDE supplementary manuscript - Submission Gastroenterology 10 Mar 2017  1 
 
Supplementary Manuscript 
 
Accuracy in Diagnosis of Celiac Disease without Biopsies in Clinical Practice  
K.J. Werkstetter1, I.R. Korponay-Szabó2,10, A. Popp,3,10, V. Villanacci4, M. Salemme4, G. Heilig1, S.T. Lillevang5, M.L. 
Mearin6, C. Ribes-Koninckx7, A. Thomas8, R. Troncone9, B. Filipiak,1 M. Mäki10, J. Gyimesi2, M. Najafi11, J. Dolinšek12, 
S. Dydensborg Sander13, R. Auricchio9, A. Papadopoulou14, A. Vécsei15, P. Szitányi16, E. Donat7, R. Nenna17, Ph. 
Alliet18, F. Penagini19, H. Garnier-Lengliné20, G. Castillejo21, K. Kurppa10, R. Shamir22, A.C. Hauer23, F. Smets24, S. 
Corujeira25, M. van Winckel26, S. Buderus76, S. Chong28, S. Husby13, S. Koletzko1, on behalf of the ProCeDE study 
group 
1 Dr. von Hauner Children’s Hospital, Ludwig-Maximilian’s University Munich 
2 Celiac Disease Center Heim Pál Children’s Hospital, Budapest and Dept. of Pediatrics, University of Debrecen, Hungary 
3 University of Medicine and Pharmacy “Carol Davila” and National Institute for Mother and Child Health “Alessandrescu-
Rusescu”, Bucharest, Romania 
4 Institute of Pathology, Spedali Civili, Bresci, Italy 
5 Dept. of Clinical Immunology, Odense University Hospital, Denmark  
6 Dept. of Pediatrics, Leiden University Medical Center, the Netherlands 
7 Dept. of Pediatric Gastroenterology and Hepatology, La Fe University Hospital, Valencia, Spain 
 8 Dept. of Pediatric Gastroenterology, Royal Manchester Children's Hospital, Manchester, United Kingdom 
9 Dept. of Translational Medical Sciences & European Laboratory for the Investigation of Food-Induced Diseases, University 
Federico II, Naples, Italy  
10 Center for Child Health Research, University of Tampere and Tampere University Hospital, Tampere, Finland 
11 Dept. of Pediatric Gastroenterology & Hepatology, Children Medical Center, Tehran University of Medical Sciences, Iran 
12 Dept. of Pediatrics, University Medical center (UMC) Maribor, Slovenia 
13 Hans Christian Andersen Children's Hospital, Odense University Hospital, Denmark 
14 Division of Gastroenterology, Hepatology and Nutrition, First Dept. of Pediatrics, Children's Hospitals "Agia Sophia", University 
of Athens, Athens, Greece 
15 Gastroenterology Outpatient Clinic, St. Anna Children's Hospital, Medical University Vienna, Vienna, Austria 
16 Dept. of Pediatrics, First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic 
17 Dept. of Pediatrics, Sapienza University of Rome, Italy 
18 Dept. of Pediatrics, Jessa Hospital, Hasselt, Belgium 
19 Dept. of Pediatric Gastroenterology, Addenbrookes Hospital, Cambridge, United Kingdom 
20 Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Hôpital Necker-Enfants Malades, Paris, France 
21 Dept. of Pediatric Gastroenterology and Nutrition, Hospital Universitari Sant Joan, Reus, Spain  
22 Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center of Israel, Sackler faculty of 
Medicine, Tel Aviv University, Tel Aviv, Israel  
23 Dept of Paediatrics, Medical University of Graz, Graz, Austria 
24 Université Catholique de Louvain, IREC, PEDI, Cliniques universitaires Saint Luc, Brussels, Belgium 
25 Dept. of Pediatric Gastroenterology, Hospital S. João, Porto, Portugal 
26 Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, Ghent University Hospital, Ghent, Belgium 
27 Dept. of Pediatrics, St. Marien Hospital, Bonn, Germany 
28 Queen Mary's Hospital for Children, Carshalton, United Kingdom 
 
 
Corresponding author:  
Prof. Dr. med. Sibylle Koletzko 
University of Munich Medical center 
Dr. von Hauner Children’s Hospital 
Lindwurmstr. 4, 80337 Munich, Germany 
Phone: +49-(0)89-44005-7855, email: sibylle.koletzko@med.uni-muenchen.de 
 
Study registration: ProCeDE is registered at German Registry for Clinical Trials, Reg-No DRKS00003555 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Werkstetter - ProCeDE supplementary manuscript - Submission Gastroenterology 10 Mar 2017  2 
 
Table of contents 
1 Supplementary methods ...................................................................................................................................... 4 
1.1 Inclusion and exclusion criteria .................................................................................................................... 4 
1.2 Pre-Screening-Log ........................................................................................................................................ 4 
1.3 Exclusion process of recruited patients ....................................................................................................... 4 
1.4 Local serology ............................................................................................................................................... 4 
1.5 Central serology ........................................................................................................................................... 5 
1.5.1 Central EMA-IgA .................................................................................................................................. 5 
1.5.2 Central TGA-IgA and DGP-IgG ............................................................................................................. 5 
1.6 Central HLA-typing ....................................................................................................................................... 5 
1.7 Endoscopy findings ...................................................................................................................................... 6 
1.8 Central reference pathology and small-intestinal biopsy morphometry analysis ....................................... 6 
1.9 Definition of patients with low total IgA ...................................................................................................... 7 
1.10 Central diagnosis .......................................................................................................................................... 7 
1.10.1 Initial approach to classify the patients .............................................................................................. 7 
1.10.2 Second approach to classify the patients ........................................................................................... 7 
1.10.3 Review of unclear cases and 1st and 2nd voting by the diagnostic committee .................................... 7 
1.10.4 Second reference pathology and 3rd voting of the diagnostic committee ......................................... 8 
1.10.5 Morphometry and 4th and final voting of the diagnostic committee ................................................. 8 
1.10.6 Diagnosis of patients with low total IgA ............................................................................................. 8 
1.11 Statistics ....................................................................................................................................................... 8 
2 Supplementary results ......................................................................................................................................... 9 
2.1 Exclusion of patients and final cohort .......................................................................................................... 9 
2.2 Symptoms and stool behaviour ................................................................................................................... 9 
2.3 Final central diagnosis .................................................................................................................................. 9 
2.4 Patients with low total IgA ........................................................................................................................... 9 
2.5 Patients with initially positive TGA-IgA but negative autoantibodies at time of biopsy ............................ 10 
2.6 HLA-negative patients ................................................................................................................................ 10 
2.7 Endoscopy and macroscopic findings ........................................................................................................ 10 
2.8 Inconclusive cases ...................................................................................................................................... 10 
2.9 Time between local TGA-IgA and biopsy .................................................................................................... 11 
2.10 False positive patients ................................................................................................................................ 11 
2.11 Accuracies and predicted probabilities of central TGA-IgA/-IgG and DGP-IgG tests ................................. 11 
2.12 Agreement between local and central EMA-IgA ........................................................................................ 11 
2.13 Agreement between local and central TGA-IgA ......................................................................................... 11 
2.14 Agreement between Eu-Gen and EUROArray HLA-typing outcomes ........................................................ 11 
2.15 Agreement between local and central HLA-typing outcomes ................................................................... 12 
2.16 Agreement between local and central histopathology .............................................................................. 12 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Werkstetter - ProCeDE supplementary manuscript - Submission Gastroenterology 10 Mar 2017  3 
 
2.17 Agreement between local histopathology and final diagnosis .................................................................. 12 
2.18 Agreement between local and central diagnosis ....................................................................................... 12 
3 Supplementary discussion .................................................................................................................................. 12 
4 Other members of the ProCeDE working group ................................................................................................ 14 
5 Supplementary figures and tables ...................................................................................................................... 15 
Figure S1: number of patients (n) from final cohort (N=707) and all recruited but excluded patients (N=96) per 
clinical study center ................................................................................................................................................ 15 
Figure S2: Flow chart on the review process of the unclear patients ..................................................................... 16 
Figure S3: Positive predictive value (PPV) for each central DGP test ...................................................................... 17 
Figure S4: Predicted probabilities for each central TGA test .................................................................................. 18 
Figure S5: Predicted probabilities for each central DGP tests ................................................................................. 19 
Figure S6: Comparison of central TGA-IgA and corresponding local TGA-IgA ........................................................ 20 
Table S1: Specifications of Local TGA-IgA and DGP-IgG.......................................................................................... 21 
Table S2: Specifications of Local EMA-IgA .............................................................................................................. 22 
Table S3: Specifications of central ELISA based tests (TGA, DGP) ........................................................................... 23 
Table S4: Specifications of central non-ELISA tests (TGA, DGP) .............................................................................. 24 
Table S5: Summary of recruited but excluded patients including reasons for exclusion ........................................ 25 
Table S6: Excluded patients compared to the patients in the final cohort ............................................................. 27 
Table S7: Gastrointestinal and extraintestinal symptoms ...................................................................................... 27 
Table S8: Characteristics of patients with low total IgA ......................................................................................... 28 
Table S9: Characteristics of patients with negative TGA-IgA at time of biopsy ...................................................... 29 
Table S10: Characteristics of patients with initially negative HLA risk alleles ........................................................ 30 
Table S11: Characteristics of inconclusive patients ................................................................................................ 31 
Table S12: Characteristics of false positive patients ............................................................................................... 32 
Table S13: Diagnostic accuracies measures for central TGA tests .......................................................................... 33 
Table S14: Diagnostic accuracies measures for central DGP tests ......................................................................... 36 
Table S15: Agreement between local and central EMA-IgA ................................................................................... 38 
Table S16: Agreement between local and central TGA-IgA .................................................................................... 38 
Table S17: Agreement between Eu-Gen-risk and EUROArray HLA-typing .............................................................. 39 
Table S18: Agreement between local HLA-typing and EurGen-risk ........................................................................ 39 
Table S19: Agreement between local HLA-typing and EUROArray ......................................................................... 39 
Table S20: Agreement between local and central Marsh-Oberhuber staging ........................................................ 40 
Table S21: Agreement between local and central histology summary ................................................................... 40 
Table S22: Agreement between local histology summary and the final central diagnosis ..................................... 41 
Table S23: Agreement between local histology statement and the final central diagnosis ................................... 41 
Table S24: Agreement between local and central diagnosis .................................................................................. 41 
6 References .......................................................................................................................................................... 42 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Werkstetter - ProCeDE supplementary manuscript - Submission Gastroenterology 10 Mar 2017  4 
 
1 Supplementary methods  
1.1 Inclusion and exclusion criteria 
Children between > 6 months to 18 years were included if they had positive TGA-IgA (any titer above 
limit of normal) or positive EMA-IgA performed in or outside the study center. In children with low total 
IgA, increased IgG-antibodies were considered. Patients had to be on gluten containing diet at time of 
biopsy. CD specific antibodies were measured because they had clinical signs or symptoms indicative for 
CD or an increased risk for CD1. Clinical symptoms indicative for CD comprised chronic or intermittent 
diarrhoea, failure to thrive, weight loss, growth retardation, delayed puberty, amenorrhoea, iron-
deficiency anaemia, recurrent nausea or vomiting, chronic abdominal pain, cramping or distension, 
chronic constipation, chronic fatigue, recurrent aphthous stomatitis (mouth ulcers), dermatitis 
herpetiformis-like rash, fracture with inadequate traumas/osteopenia/osteoporosis, abnormal liver 
biochemistry. Conditions associated with increased risk for CD included type 1 diabetes mellitus, Down 
syndrome, autoimmune thyroid disease, Turner syndrome, Williams syndrome, selective IgA deficiency, 
autoimmune liver disease, and having a 1st degree relative with CD. 
Exclusion criteria comprise negative TGA and EMA antibodies, contraindications for endoscopy or 
biopsies or refusal of the parents to perform the biopsies, malignancy, serious chronic infections such as 
HIV or tuberculosis or congenital immunodeficiency, immune suppressive drugs, language barriers 
which did not allow to give informed consent or no signed informed consent form.  
1.2 Pre-Screening-Log 
The clinical center listed all patients that were considered to be eligible for study participation due to 
positive TGA-IgA (or TGA-/EMA/DGP-IgG in case of low total IgA) on the pre-screening-log. The log-file 
was submitted to the study management (K.W.) at the end of each month and reviewed for consistency.  
The basic information on the pre-screening-log included the date when the patients were considered to 
be eligible, the TGA-IgA level, and if the in/exclusion were fulfilled and the patient recruited. If not, the 
reason why the patient was not recruited (e.g. “refused to biopsy”) was briefly indicated. If the patient 
met all inclusion criteria and was recruited, additional information on month and year of birth and 
potential date for biopsy were listed and the patient-ID was assigned.  
1.3 Exclusion process of recruited patients 
Patients were retrospectively excluded if it became evident that in- or exclusion criteria were not 
fulfilled, if the dataset was incomplete for relevant information from the clinical center (no information 
on clinical presentation, local serology or local histopathology), if serum for central serology was not 
available, if neither local nor central HLA-typing was done, if histology specimen were not provided for 
the reference histology, if the first or second reference pathologist and morphometry analysis revealed 
that the histology specimen was non-evaluable due to low quality or orientation problem, or if mix-up of 
serum samples was obvious.  
 
1.4 Local serology 
Local serology should have been done maximum two weeks prior to or at time of biopsy. There have 
been ten different TGA-IgA tests applied in the laboratories of the local clinical centers (table S1), 
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however, even if the same test was used the limits of normal (locally applied cut off) varied in between 
the laboratories. 
For EMA, there were 14 different tests (table S2). In 13/32 laboratories titration to the highest dilution 
still giving a positive results was performed and the report indicated this dilution. All other laboratories 
only reported if the sample was negative or positive or gave a grading for positivity (+, ++, +++).  
1.5 Central serology 
In total, 16 tests from 5 different manufacturers have been included in the panel for central serology 
analyses.  
1.5.1 Central EMA-IgA 
Immunofluorescent analysis of EMA-IgA (EMA-IgG if low total IgA) was performed by one experienced 
bioanalyst (G.H., Dr. von Hauner Children’s Hospital, Munich, Germany). Serum was diluted 1:5, 1:10, 
1:100, 1:1000 in phosphate-buffered saline and 1:2.5 if the 1:5 dilution gave a negative result. The 
diluted sera were incubated for 30 minutes on EUROIMMUN IIF mosaic slides combining BIOChips of 
monkey esophagus and liver tissue (FA 1911-3 A/G, EUROIMMUN Medizinische Labordiagnostika AG, 
Lübeck, Germany) according to manufacturer’s instructions. After washing with PBS-Tween the 
BIOCHIPs were incubated for another 30 minutes with FITC-labelled anti-human-IgA or IgG (goat) 
conjugate and washed again with PBS-Tween. The BIOCHIPs were examined on a fluorescence-
microscope (Standard 16, serial number 1047060, Zeiss, Jena, Germany). A signal in 1:2.5 dilution or 
higher was considered positive.  
1.5.2 Central TGA-IgA and DGP-IgG 
All ELISA-based tests were run in single determinations by the same bioanalysts in the central laboratory 
(Dept. of Clinical Immunology, Odense University Hospital, Denmark) on one automatized ELISA 
platform (EUROIMMUN Analyzer I, EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, 
Germany). Please find the details on the analysis and calibration for all ELISA tests in table S3.  
There were four non-ELISA-based tests which need to run on specialized automatized systems, thereof 
two tests from Thermo Fisher/Phadia which were run on the Phadia250 machine (Fluoescence Enzyme 
Immunoassay; Dept. of Clinical Immunology, Odense University Hospital, Denmark) and two tests from 
INOVA diagnostics which were run on the BIO-FLASH machine (chemiluminescence technique; done by 
G.H. at Werfen GmbH, Kirchheim, Germany). Please find the details on these tests in table S4. 
 
1.6 Central HLA-typing 
An EDTA-full blood sample was taken at the clinical center around the time of biopsy and DNA was 
either directly isolated by the lab of the clinical center and frozen at -20°C or the full blood was stored at 
-20°C until shipment to the central laboratory for DNA isolation in Munich, Dr. von Hauner Children’s 
hospital, with the Qiagen Minikit on the QiaCube (Qiagen GmbH, Hilden, Germany). In Munich, all DNA 
samples were aliquoted and patient IDs were re-coded to guarantee data security before sending the 
samples to Eurospital SpA (Trieste, Italy) and Euroimmun GmbH (Lübeck, Germany) for HLA typing.  
The Eu-Gen-risk test (Eurospital SpA) is based on two series of eight PCR tubes where primers for 
amplification of individual DQA1, DQB1 and DR alleles are present. Each tube provides with a single 
results with the only exceptions of tubes #7 (B1*03:01 and B1*03:03) and #8 (B1*03:01 and B1*03:04) 
where two alleles are present. Doing so it is always known whether B1*03:01 or B1*03:03 or B1* 03:04 
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alleles are present. If there is a positive result is in both tubes, this means that the B1*03:01 allele is 
present. If the positive result is only found in one position (e.g. tube #7) the positivity will refer to the 
B1*03:03 allele. Vice versa if the positivity is only in tube #8, then it refers to B1*03:04. In total, the 
following 16 alleles were typed: DQA1*01, DQA1*02:01, DQA1*03, DQA1*05, DQA1*06, DQB1*02, 
DQB1*03:01 and DQB1*03:03, DQB1*03:01 and DQB1*03:04, DQB1*03:02, DQB1*03:05, DQB1*04, 
DRB1*03, DRB1*04, DRB1*07, DRB1*11; results were expressed in terms of: DQ and DR genotypes, 
complete Haplotypes and Homo- or Heterozygosis status.  
HLA-DQ2.2, -DQ2.5 and -DQ8 determination by EUROArray HLA-DQ2/DQ8 was performed according to 
manufacturer’s instructions (EUROIMMUN Medizinische Labordiagostika AG, Luebeck, Germany) for 
HLA-typing. Briefly, sequence specific amplification of all relevant HLA-DQ alleles was achieved by 
multiplex PCR with simultaneous fluorescence labelling of the reaction products. PCR products were 
resolved by hybridization to specific probes on a EUROArray slide using TITERPLANE incubation 
technique. Spot intensities were analyzed by the EUROIMMUN Microarray Scanner. Finally, celiac 
disease associated HLA-DQ alleles and genotypes were automatically deduced by the EUROArrayScan 
software. 
In patients with negative HLA-risk alleles but with positive central serology and reference 
histopathology, a 3rd HLA-typing with DNA material from a new blood sample to exclude sample 
confusion was performed by SNP tests2, the Olerup low resolution DQ typing kit, and the B*03 subtyping 
kits to identify rare risk alleles. 
 
1.7 Endoscopy findings 
The clinical centers reported on a standardized questionnaire all macroscopic findings if upper 
endoscopy was performed, including  erosive esophagitis indicating reflux disease , findings of 
eosinophilic esophagitis (furrors, rings, narrowing), gastric and duodenal  nodularity, erosions and ulcer 
and if available also the  Helicobacter pylori status based on histology, rapid urea test and/or culture.  
1.8 Central reference pathology and small-intestinal biopsy morphometry analysis 
The clinical centers were asked to take at least five forceps biopsies during upper endoscopy, at least 
four from the pars descendens duodeni and at least one from the duodenal bulb (Husby). One center 
still performed capsule biopsies resulting in only one or two tissue samples per case. All local 
pathologists gave written agreement before inclusion of the center to fill a structured histology report 
including Marsh staging. They were asked to provide four hematoxylin and eosin (H&E) stained slides 
(including at least one biopsy from the duodenal bulb if available), and one or two unstained slides 
which to the referral center for immunohistochemical evaluation of the number of intraepithelial T 
lymphocytes using anti-CD3 monoclonal antibodies. The central histopathology report was based on the 
Marsh-Oberhuber Classification 3,4 and included information on number of IEL (< or ≥25 IEL /100 
enterocytes) and orientation of the biopsies. If there were more than 1 biopsy fragment (usually 5-6) 
and with different degrees of villous atrophy, the highest grade was attributed to the case. To fulfill the 
criterion of CD enteropathy Marsh 2 or higher was required.  
In patients with inconsistent histopathology outcomes or with biopsy specimen that were non-evaluable 
by standard histopathological techniques, the original biopsies (paraffin blocks) were requested if 
possible. Morphology of these biopsies was then again evaluated using validated quantitative 
morphometry according to standard operating procedures (SOP)5,6. The assessment was performed on 
hematoxylin-eosin stained 2µm sections of paraffin embedded mucosal samples. The investigator (A.P., 
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Bucharest and Tampere) identified correctly oriented sections where reliable morphometric 
measurements could be obtained, i.e. perpendicular sectioning as to the mucosal surface so that crypts 
were cut longitudinally and not in cross sections. At least three readable villus-crypt units were 
demanded for the evaluations according to the SOP. The villus heights (VH, µm) and corresponding crypt 
depths (CrD, µm) were measured and results were given as the mean ratio of the measurements 
(VH:CrD). A VH:CrD equal or more than 2 was considered normal. For the samples with poor orientation 
additional cuttings were requested and reassessment was done. If no units had been measured even 
after re-cuttings, the sample was classified as not measurable. If one or two units only were measured, 
the VH:CrD was given but the evaluator stated this was not according to the SOP. 
 
1.9 Definition of patients with low total IgA 
Since patients with deficient or low total IgA may not produce sufficient TGA-IgA, we tested patients 
with total IgA below 0.25 g/l and negative TGA-IgA for IgG-based antibodies (both in local and central 
lab). If local total IgA was not available but TGA-IgA was >3x ULN, the patient was considered to have 
normal total IgA. If local total IgA was not available but TGA-IgA was ≤3x ULN, then the total IgA was 
repeated in central lab (Odense or Munich).  
All patients with low total IgA were excluded from the main data analysis but separately analyzed as a 
subgroup.  
 
1.10 Central diagnosis  
The process how initially unclear patients were finally classified into the categories “proven CD”, “no 
CD” and “inconclusive” is described in the following. Please also see figure S2 which provides an 
overview on this process.  
1.10.1 Initial approach to classify the patients 
Proven CD was considered if the local TGA-IgA was above the respective limit of normal, the local and 
the central EMA-IgA were positive, the HLA-genotype was associated with CD risk and if both the local 
and the reference pathologist gave at least ≥ Marsh 2.  
Celiac disease was excluded if none of the above criteria were fulfilled. All other patients were initially 
regarded as unclear.  
Patients with low total IgA (see 1.8) were analyzed as a separate group. 
1.10.2 Second approach to classify the patients 
The diagnostic committee decided to also classify patients as proven CD patients if 1) only the local 
EMA-IgA was negative but all other criteria were positive or 2) if the local pathologist did not report any 
Marsh staging but stated that the histology findings were indicative for CD and this was in line with the 
reference pathologist.  
CD was also excluded if only the local TGA-IgA was positive but below the 3x ULN and if all other 
outcomes including the central serology were negative.  
1.10.3 Review of unclear cases and 1st and 2nd voting by the diagnostic committee  
All remaining unclear cases were reviewed by the diagnostic committee (reviewers S.K., I.K., C.R., L.M, 
R.T, S.H., A.T.).  
The Center-Patient IDs (identification numbers) were re-coded to avoid that the reviewers might be 
biased by the origin of the patient or the responsible clinical center.  
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For each patient a summary were available for the reviewers, including symptoms, risk factors and 
relevant findings in physical examination, local and central serology and histopathology results. 
However, for the central serology (TGA and DGP) not the raw numbers (titer levels) were shown but a 
summary of how many TGA-IgA or DGP-IgG tests were positive, meaning above limit of normal 
according to the manufacturer’s instructions (e.g. 4/8 TGA-IgA tests positive).  
The voting was done anonymously and the reviewers chose one of the following options: proven CD, no 
CD, and unclear case. If the majority (at least four of seven reviewers) agreed on the diagnosis of CD or 
the exclusion of CD, the unclear case was solved. If there was no agreement, the patient was still 
regarded as unclear.  
If the committee considered that any relevant information was missing or that there was doubt about 
the current results, the clinical center or the central laboratories were approached and the new 
information was included in the summary and a second review process was done.  
In the 2nd review process, unclear cases were also distinguished in potential CD (seropositivity but 
normal histology) or unclear cases due to inconsistent clinical picture due to either inconsistency 
between serology and histology or between the local and the reference pathologist.  
1.10.4 Second reference pathology and 3rd voting of the diagnostic committee  
For all potential and unclear cases, the centrally available histology sections were examined by a second 
reference pathologist (D.A., Dresden) who was blinded to any clinical information on the patients. The 
new pathology report was included in the 3rd voting of the diagnostic committee.  
1.10.5 Morphometry and 4th and final voting of the diagnostic committee 
For the remaining cases, the original biopsies (paraffin blocks) were collected from the pathology 
department of the clinical centers and morphometry analysis including measuring villous-crypt-ratio was 
done as described above by a pediatric gastroenterologist (A.P. Bucharest and Tampere) who is 
specialised in CD morphometry (see 1.7). Again, the investigator was blinded for all clinical data of the 
patients.  
Afterwards, the 4th and final voting was done by six of initially seven members of the committee (S.K., 
I.K., C.R., L.M, R.T, S.H.). If histology specimen were finally considered as non-evaluable, the patients 
were excluded for this reason.  
If the final classification into “proven” or “no CD” was still not possible after the 4th review process, the 
remaining unclear patients were then considered to be inconclusive.  
1.10.6 Diagnosis of patients with low total IgA 
The diagnostic approach of patients with low total IgA was similar to the process described above for 
patients with sufficient total IgA titers, however, TGA-IgG, DGP-IgG and EMA-IgG antibodies were 
considered. Morphometry analysis was not done in these patients but was also not necessary.  
 
1.11 Statistics 
Mean±SD and/or median and minimum to maximum were indicated for continuous variables. 
Proportions were given in percent. Differences between the excluded patients and the final cohort were 
tested with the Wilcoxon sum rank test.  
For each central TGA-IgA and DGP-IgG tests the optimal ULN to diagnose CD was determined if the 
lower bound of the PPV’s 95% CI reached ≥ 99%.  
The probability for positive disease was estimated by logistic regression and the predicted line with 95% 
confidence limits and the observations were displayed. 
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Inter-observer agreements between local and central outcomes for histopathology and EMA and for the 
two HLA-typing tests were given as simple kappa coefficient with 95% CI. A kappa coefficient of 0 to 0.20 
was considered as slight, 0.21 to 0.40 as fair, between 0.41 to 0.60 as moderate, 0.61 to 0.80 as 
substantial, and 0.81 to 1.00 as (almost) perfect agreement. Level of significance was α=0.05 for all 
tests. The manuscript was written in accordance with the STARD-statement7. 
2 Supplementary results 
2.1 Exclusion of patients and final cohort 
All excluded patients and the reasons for exclusion are summarized in table S5.  
Compared to the patients included in the final cohort, the excluded patients (except patients with total 
IgA deficiency) tended to be younger with a median age of 4.3 versus 6.2 years (p=0.09, Wilcoxon sum 
rank test) and the median for the multiple of the ULN for the local TGA-IgA was significantly lower with a 
5.3 versus 11.8 (p<0.001). For details see table S6.  
The distribution of all patients, stratified in patients in the final cohort and excluded patients, is shown 
for all centers in figure S1.  
2.2 Symptoms and stool behaviour 
Parents and patients were asked to report symptoms and stool pattern, considering the period four 
weeks prior to study visit. Abdominal pain was the most frequent gastrointestinal (50.6%) and weight 
loss respectively insufficient weight gain the most commonly reported extraintestinal symptom (30%). 
The frequency of all reported symptoms is summarized in table S7.  
According to the Bristol stools scale (BSS), 13.0% reported hard stools (BSS type 1-2), 68.6% normal 
consistency (BSS type 3-5) and 18.4% mushy to liquid stool (BSS type 6-7). Stool frequency was ≤ 2 stools 
per week in 8.6%, 3 to 4 stools per week in 15.8%, 1-2 stools per day in 61.4% and ≥3 stools per day in 
14.2% of patients. 
2.3 Final central diagnosis 
After the initial approach to classify the patients into proven and no CD, 189 patients remained unclear, 
thereof 4 with negative HLA. As a result of the diagnostic review process, 16 patients were finally 
classified as finally inconclusive and 29 had to be excluded from analysis mostly due to non-evaluable 
histology. For details see figure S2.  
2.4 Patients with low total IgA 
In total, 17 patients fulfilled the criteria for low total IgA, thereof one patient had a total IgA of 0.23g/l, 
negative TGA-IgA but positive DGP-IgG, positive central EMA-IgG (1:1000) and positive local and central 
histopathology. Eleven patients were diagnosed as proven CD, in five CD was excluded and one patient 
was considered to have potential CD and remained inconclusive. The summary of all patients with low 
total IgA is shown in table S8.  
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2.5 Patients with initially positive TGA-IgA but negative autoantibodies at time of 
biopsy 
Twenty-nine patients had negative TGA-IgA at time of biopsy; thereof 10 had also negative local EMA-
IgA. All of them had a previously positive TGA-IgA titer either done outside or in the clinical center. The 
characteristics of these patients are summarized in table S9. 
2.6 HLA-negative patients 
In total, 18/707 patients were initially HLA-negative (table S10). For 2/18 patients with high suspicion of 
CD, the 2nd typing from newly drawn blood samples were HLA-positive in both. One of these two 
patients was positive for DQ2 in the second sample and the initial negative sample was DNA from the 
father, in whom blood was initially drawn the same day and was mixed up with the son’s blood. In the 
second child, the typing was positive in SNP and DQB1*03 subtyping analysis for one copy of the CD-
related DQ9 allele (DQB1*0303)8 and a rare haplotype with an unusual hybrid allele DR7-DQA1*0201-
B1*0301/0303 and thus a HLA status resembling to DQ2.2/DQ7 (DQ2 in trans) was found. None of the 
remaining 16 patients with negative HLA or DQA1*05 was diagnosed with CD. Details on all HLA-
negative patients are summarized in table S10. All of them had local TGA-IgA below 3xULN, four 
patients had at least one positive central TGA-IgA results and five at least one positive DGP-IgG titer. Of 
note, central and local EMA-IgA were negative in all 16 patients, indicating a higher specificity of EMA 
compared to TGA and DGP antibodies. 
2.7 Endoscopy and macroscopic findings 
Information on macroscopic findings at endoscopy was reported in 653 who underwent endoscopy, 54 
(7.6%) were biopsied with capsule. Information on H. pylori status from gastric biopsies was available in 
442.  
Esophageal findings  
Erosive esophagitis indicating gastroesophageal reflux disease (GERD) was identified in 24/653 (3.7%) 
patients. No case of eosinophilic esophagitis was reported.  
 
Gastric findings 
H. pylori infection was found in 20 of 442 (4.5%) patients with known H. pylori status. Erosions were 
found in 21/653 (3.2%) patients, 2/21were H. pylori infected, 16 were not infected and in the remaining 
three the H. pylori status was unknown. No gastric ulcer was reported in the 653 patients.  
Duodenal findings 
Erosions were found in 41/653 (6.3%) patients, with only one of them being infected with H. pylori, 33 
were not infected and in the remaining the infectious status was unknown. Two patients had a duodenal 
ulcer (0.3%), one was not infected with H. pylori, and in the second H. pylori status was not assessed. 
 
2.8 Inconclusive cases 
Finally 16 patients remained inconclusive and had no clear diagnosis, thereof nine were classified as 
potential CD with positive serology but negative histology and seven patients were considered as 
inconclusive due to contradictory results. Details on all inconclusive cases are summarized in table S11.  
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2.9 Time between local TGA-IgA and biopsy 
In 563 patients, the time gap between local TGA-IgA and biopsy was <14 days. The median time 
between local serology and biopsy was 0 days (minimum 0 days, maximum 304 days). Of 144 patients 
with time gap >13 days, 135 patients had proven CD, 7 patients were finally considered as no CD and 
two patients were inconclusive, thereof one with a time gap of 16 days and one with 54 days (see 
supplementary table S12.  
2.10 False positive patients 
Details on the eight patients with high TGA-IgA (>10xULN) either at the local or at least one central test 
but with either no CD (N=2) or inconclusive diagnosis (n=6) are summarized in table S12. In six patients, 
there was no villous atrophy seen by neither the local nor the reference pathologists. For one patient, 
villous atrophy was found in the bulb only in morphometry analysis and for two other patients the 
biopsy specimen and therefore the morphometry analysis were not available. For another patient, both 
the local and the reference pathologist graded Marsh 1, the second reference pathologist gave Marsh 3 
while morphometry analysis showed normal crypt-height ratio. One patient had clear villous atrophy 
(Marsh 3) in all histology examinations but all central TGA-IgA and EMA-IgA were negative with normal 
total IgA and 4/6 positive DGP-IgG results. The high discrepancy between local TGA level (20xULN) and 
none of eight central TGA-IgA tests giving a level above cut off, is not to explain. A wrong labelling of 
local or central serum samples or biopsies cannot be excluded but in contrast to other cases, there was 
no prove for sample mix-up and therefore the diagnostic committee decided to not exclude this patient.  
2.11 Accuracies and predicted probabilities of central TGA-IgA/-IgG and DGP-IgG tests 
The diagnostic accuracies including sensitivity, specificity, positive predictive value (PPV) and positive 
likelihood ratio (LR+) for the central TGA results are summarized in table S13. For the central DGP-tests 
the accuracies are summarized in table S14 and the PPV with 95% CI band in figure S3.  
The predicted probabilities for the multiples of each central TGA and DGP test are shown in figure S4 
and S5.  
2.12 Agreement between local and central EMA-IgA 
Comparing the local and the central EMA-IgA results (categorized in “positive” and “negative” according 
to the respective test instructions), there was an agreement in 93.75% of the patients (N=704) and the 
kappa coefficient was 0.65 [0.56;0.75]. For details, see table S15. 
2.13 Agreement between local and central TGA-IgA 
In 334 patients the local TGA-IgA was analyzed with a test that was also included in the TGA-IgA test 
panel of the central serology, and the sera that were used for local and central serology were taken on 
the same day. In figure S6 the correlation between the local and the corresponding central TGA-IgA titer 
are shown.  
Comparing the ≥10 ULN for the local TGA-IgA and the corresponding TGA-IgA result of the central lab 
(table S16), the agreement was 86.5% and the kappa coefficient was kappa -0.597 [-0.6966; -0.4978]. If 
local laboratories have applied different levels of normal than those suggested by the manufacturer and 
applied for central test, the 10x ULN was calculated with the level of normal that was indicated by the 
local laboratory, as the real situation should be given.  
2.14 Agreement between Eu-Gen and EUROArray HLA-typing outcomes 
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In 695 patients, there were valid typing results available both for EU-Gen-risk and EUROArray HLA-
DQ2/DQ8. The agreement was 97.6% with a high kappa coefficient of 0.93 [0.90;0.96]. Particularly 
depending on two different variants for the definition of HLA-DQ8 positivity of the EUROArray, the 
agreement may vary. For details see table S17. 
2.15 Agreement between local and central HLA-typing outcomes 
In 151 patients both local and central HLA-typing was available. For the comparison between the local 
typing and the EU-Gen-risk (Eurospital S.p.A), the agreement was 92.1 % and the kappa coefficient 0.74 
[0.61;0.88], for details please see table S18. For the comparison between the local typing and the 
EUROArray HLA-DQ2/DQ8 (EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany), the 
agreement was 92.1 % and the kappa coefficient 0.74 [0.60;0.88], for details please see table S19.  
2.16 Agreement between local and central histopathology 
The agreement in the Marsh-Oberhuber (0 to 3C) staging between local histopathology versus reference 
histopathology is 41.7 % with a kappa coefficient of 0.20 [0.15; 0.25]. However, in 31 patients no local 
Marsh staging was available as the local pathologist considered it not feasible. For details please see 
table S20.  
When summarizing the Marsh-Oberhuber stagings in the two main outcomes indicative for CD (Marsh 2 
or 3A-C) or not (Marsh 0 and 1), the kappa coefficient for the agreement between local and central 
histopathology was 92.9% with a kappa coefficient of 0.66 [0.57;0.75]. For details please see table S21. 
2.17 Agreement between local histopathology and final diagnosis 
Table S22 shows the comparison between the summarized Marsh-Oberhuber staging in the two main 
outcomes indicative for Celiac Disease (Marsh 2 or 3A-C) or not (Marsh 0 and 1), we found 3 patients in 
whom the local pathologist considered CD but the final diagnosis was “no CD”. Vice versa, there were 37 
patients in whom the local pathologist evaluation resulted in Marsh 0 or Marsh 1 but the final central 
diagnosis was “proven CD”. Overall, there were 40 cases in whom the local histopathology gave the 
wrong statement when considering the central diagnosis as reference.  
Table S23 also includes the patients for whom the local pathologist did not indicate a Marsh staging but 
gave a general statement if the specimen is normal or pathologic but not indicative with CD or is 
compatible with CD.  
2.18 Agreement between local and central diagnosis 
When comparing local and final central diagnosis, there was one patient false positive for proven CD in 
the local clinical center and “proven CD” in the central diagnosis. Furthermore, eight patients were 
classified false negative as “no CD” by the clinical center but were considered to be “proven CD” in the 
final central diagnosis. For more details, see Table S24. As the local clinical centers had less information 
on the patient than the central diagnostic committee, no kappa coefficient was calculated.  
3 Supplementary discussion  
Our prospective multicentre study with extensive local and central diagnostic work up demonstrates 
that in the real life situation the diagnosis of CD may be complex with a high percentage of cases 
showing discordant results for TGA-IgA (negative vs positive, any positivity vs high positive), EMA 
(positive vs negative) and histology (indicative for CD vs no CD). The concordance regarding EMA results 
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was surprisingly high in spite of the low experience with EMA measurement in some centers, which only 
started EMA testing for the purpose of the ProCeDE study. In contrast, the inter-observer agreement 
between the local and the central reference pathologist regarding the diagnosis of CD “Yes” or “No” was 
not satisfactory. In 48 of 676 cases in which the local pathologist provided Marsh staging, there was 
disagreement regarding the final diagnosis of CD between the pathologists (Marsh 2 or 3 vs Marsh 0 or 1 
(table S21). Our results confirm that there is not a single diagnostic test with a sufficiently high 
sensitivity and specificity which could serve as reference standard. Therefore, we had planned from the 
very beginning of the study that the final diagnoses “CD” or “no CD” had to be based on a combination 
of test results. Each of the different diagnostic tests had to be tested for its accuracy against this final 
diagnosis. Our results clearly demonstrate that previous studies cannot be considered as reliable in 
which laboratory tests (HLA-typing, TGA, EMA or DGP serology) were validated against histology as only 
reference 9-18.  
The ESPGHAN-guidelines do not consider DGPs for the criteria of the non-biopsy approach1. Some 
publications suggest combining TGA and DGP tests 19,20, while others concluded that adding DGP does 
not improve accuracy 21,22. The 10xULN of the DGP tests analyzed in our central lab showed PPVs of 
100% for almost all six tests. However, the proportion of CD cases having DGP-IgG titers >10xULN was 
much lower (range 2.48 - 48.9%) compared to TGA-IgA (57.8 - 84.7%). This study was not designed to 
evaluate the sensitivity or specificity of DGP-IgG or TGA tests for case findings. Our results are biased 
towards TGA testing since a positive TGA results was one of the inclusion criteria. Therefore, we may 
have missed some CD cases with negative TGA-IgA results but positive DGP results. This is certainly true 
for IgA deficient patients, and may rarely occur in others with low TGA titers. Further, this study did not 
evaluate occurrence of DGP positivity in other conditions or healthy people. However, we are not aware 
of any published case of an IgA competent patient with negative TGA-IgA results but very high 
(>10xULN) DGP results and biopsy proven CD. Future studies testing patients with suspected CD with the 
combination of TGA-IgA and DGP-IgG instead of total IgA including a cost calculation considering is 
necessary to decide on the recommendation for initial testing. 
Potential risk of missing other endoscopy findings 
Patients with untreated celiac disease commonly have esophageal dysmotility and delayed gastric 
emptying which may increase their risk for GERD. These motility alterations resolve on a gluten free diet 
23. The prevalence of H. pylori infection in our cohort was surprisingly low considering that we recruited 
in countries with high prevalence of H. pylori infection in children such as Israel, Iran, Russia and some 
Eastern and Southern European countries. H. pylori infection is mostly acquired within the first 5 years 
of life and persists without therapy. Epidemiological studies showed an inverse relationship between H. 
pylori infection and immune mediated disorders including inflammatory bowel disease 24, childhood 
asthma 25, and celiac disease 26 suggesting a protective role of H. pylori infection. Macroscopic duodenal 
erosions and shallow ulcerations are well known findings in celiac enteropathy. They resolve with a 
gluten free diet. In summary, endoscopic pathological findings were unfrequently reported in this 
cohort. Most of the pathologies were likely to be related to untreated celiac disease and expected to 
resolve on a gluten free diet. The H. pylori infection rate was low. Erosions were not more frequently 
observed in infected compared to non-infected children. No peptic ulcer disease was found in H. pylori 
positive children. H. pylori gastritis in the absence of ulcer disease in children is no indication for therapy 
27. Our findings indicate that the non-biopsy approach is not resulting in disadvantages for these children 
due to missed co-morbidities.  
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4 Other members of the ProCeDE working group 
Piotr Socha, MD, PhD, Department of Gastroenterology, Hepatology, Nutritional Disorders and Pediatrics and Prof. 
Bozena Cukrowska, Pathology Department, Children's Memorial Health Institute, Warsaw, Poland; Hania 
Szajewska, MD, PhD, Pediatrics, Medical University of Warsaw and Jan Wyhowski, MD, Pathomorphology, 
Pediatric University Hospital, Warsaw, Poland; Nailah Brown and Gauri Batra, MD, Royal Manchester Children’s 
Hospital, Manchester, UK; Zrinjka Misak, MD, PhD, the Referral Center for Pediatric Gastroenterology and 
Nutrition, Children’s Hospital Zagreb, and Sven Seiwerth, MD, PhD, Institute of Pathology, Medical School 
University of Zagreb, Zagreb, Croatia; Yulia Dmitrieva, MD, PhD, and Dmitry Abramov, MD, FSCC PHOI, Russian 
Medical Academy of Continuing Postgraduate Education; Yvan Vandenplas, MD, PhD, and Annieta Goossens, MD, 
PhD, Pathology, Kidz Health Castle, UZ Brusses, Brussel, Belgium; Maaike W. Schaart, MD, PhD, Pediatrics, and 
V.T.H.B.M. Smit, MD, PhD, Pathology, Leiden University Medical Center (LUMC); Nicolas Kalach, MD, PhD, and 
Valerie Vasseur, Hôpital Saint Vincent de Paul, Catholic University Judit B. Kovács, MD, PhD and Anikó Nagy, MD, 
Gastroenterology & Nephrology, Ilona Lellei MD, and Rita Kőbányai MD, Pathology, Heim Pál Children's Hospital, 
Budapest; Katayoun Khatami, MD, PhD, Pediatric Gastroenterology, Hepatology &Nutrition, Children Medical 
Center, Tehran University of Medical Science and Mofid Children Hospital, Shahid Beheshti University of Medical 
Sciences, and Maryam Monajemzadeh, MD, PhD, Pathology Unit, Children Medical Center Hospital Tehran; 
Konstantina Dimakou, MD, Division of Gastroenterology and Hepatology, First Department of Pediatrics, and 
Amalia Patereli, MD, Children’s hospital «Agia Sofia», University of Athens; Tine Plato Hansen, MD, Clinical 
Pathology, Odense University Hospital; Rajko Kavalar, MD, PhD, Department of Pathology, University Medical 
Center Maribor, Maribor, Slovenia; Miguel Bolonio, Pediatric Gastroenterology & Hepatlogy and David Ramos, 
Pathology Unit, La Fe University Hospital Valencia; Hubert Kogler, MD, St. Anna Children's Hospital, Gabriele 
Amann, MD, Department of Pathology, Medical University Vienna; Roberta Kosova, MD and Mariantonia Maglio, 
PhD, Dept. of Translational Medical Sciences & European Laboratory for the Investigation of Food-Induced 
Diseases, University Federico II, Naples Italy; Elke Janssens, MD, Pediatrics, and Ruth Achten, MD, Pathology, Jessa 
Hospital, Hasselt; Pavel Frűhauf, MD, PhD, Pediatrics and Adolescent Medicine, and Helena Skálová, MD, 
pathologist, Institute of Pathology, First Faculty of Medicine and General University Hospital, Charles University, 
Prague, Czech Republic; Thomas Kirchner, MD, PhD, Institute of Pathology, Ludwig Maximilian's University Munich, 
Munich, Germany; Laura Petrarca, MD, Pediatrics and Infantile Neuropsychiatry, and Fabio Massimo Magliocca, 
MD, Radiology, Oncology and Human Pathology, “Sapienza” University, Rome, Italy; Francesc Martínez, MD, 
Gastroenterology Unit and Vanesa Morente, PhD, Pathology Unit, Hospital Universitari de Sant Joan de Reus, IISPV, 
URV; Sonja Thanner-Lechner, MSc, Pediatrics, and Manfred Ratschek, MD, Institute for Pathology, Medical 
University of Graz, Austria; Marco Gasparetto, MD, Pediatric Gastroenterology, Hepatology & Nutrition, and Liz 
Hook, MD, Pathology, Cambridge University NHS Foundation Trust, Addenbrookes Hospital, Cambridge, UK; 
Danielle Canioni, MD, Anatomo-Pathology, Hôpital Necker-Enfants Malades, Paris, France; Catherine Wanty, MD, 
Pediatric Gastroenterology and Anne Mourin, MD, Pathology Unit, Université Catholique de Louvain, Cliniques 
universitaires Saint Luc, Brussels, Belgium; Kaija Laurila, MSc, and Martine Vornane, MD, Centre for Child Health 
Research, University of Tampere and Tampere University Hospital, Tampere, Finland; Vered Nachmias Friedler, 
MD, Institute of Gastroenterology, Nutrition & Liver Diseases, Schneider Children's Medical Center and Sara L. 
Morgenstern, MD, Department of Pathology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv 
University, Israel; Jorge Amil Dias, MD, and Fátima Carneiro, MD, PhD, Hospital S. João, Porto, Portugal; Stephanie 
Van Biervliet, MD, PhD, and Saskia Vande Velde, Dept. of Pediatric Gastroenterology, Hepatology and Nutrition, 
Ghent University Hospital, Gent, Belgium; Hany Banoub, MD, Queen Mary's Hospital for Children, and Steve 
Sampson, Dept of Pathology, Epsom & St Helier University NHS Trust, Carshalton, UK; Annette M. Müller, MD, PhD, 
Department of Pathology, University of Bonn, Bonn, Germany; Adina Ene, MD, Histology Department National 
Institute for Mother and Child Health, Bucharest, Romania; Mandana Rafeey, MD, PhD, Liver & Gastrointestinal 
Research Center and Iran Amir Taher Eftekhar Sadat, MD, PhD, Pathology Unit, Tabriz University of Medical 
Sciences;   
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5 Supplementary figures and tables 
Figure S1: number of patients (n) from final cohort (N=707) and all recruited but excluded patients (N=96) per clinical study center  
Figure S1: Number of patients (n) from final cohort (N=707) per clinical study center plus all recruited but excluded patients due to non-evaluable 
histopathology, low total IgA or other reasons (N=96)
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Figure S2: Flow chart on the review process of the unclear patients 
Figure S2: Flow-chart of the diagnostic review process of unclear cases from the first approach until the 
final decision after the 4th review; when this review process was completed, patients without definitive 
final central diagnosis were then named inconclusive.  
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Figure S3: Positive predictive value (PPV) for each central DGP test 
Figure S3: Positive predictive value (PPV) with 95% CI band (grey shaded) for CD diagnosis for each of the six central DGP-IgG tests (D1 to D6); the x-axis shows 
the multiple of the respective limit of normal according to the manufacturers‘ instructions (all truncated at 10xULN except test D5 which is truncated at 8xULN 
due to limited maximum measuring range of the antibodies in the central laboratory). The y-axis shows the PPV. Please see table 3 for the names and 
manufacturer of each test.  
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Figure S4: Predicted probabilities for each central TGA test 
Figure S4: Predicted probabilities with 95% CI band (grey shaded) of the CD diagnosis (yes=1, no=0) for central TGA-tests, including eight TGA-IgA tests (T1 to T8) 
and one TGA-IgG test (T9); the x-axis shows the multiple of the respective limit of normal according to the manufacturers‘ instructions (all truncated at 11xULN). 
The y-axis shows the probabilities for CD diagnosis. Please see table 3 for the names and manufacturer of each test. 
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Figure S5: Predicted probabilities for each central DGP tests 
Figure S5: Predicted probabilities with 95% CI band of the CD diagnosis (yes=1, no=0) for central DGP-IgG tests (D1 to D6); the x-axis shows the multiple of the 
respective limit of normal according to the manufacturers‘ instructions (all truncated at 11xULN ). The y-axis shows the probabilities for CD diagnosis. Please see 
table 3 for the names and manufacturer of each test. 
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Figure S6: Comparison of central TGA-IgA and corresponding local TGA-IgA 
Figure S6: Correlation between TGA-IgA-titers of the local laboratory and the titer of the corresponding TGA-IgA 
test in the central laboratory panel if included, and if both local and central test were analyzed from serum taken 
at the same day (N=334); as the local laboratories usually only measured up to the maximum measuring range for 
a certain test (100 U/ml, 128 U/ml or 200 U/ml), the central results were truncated to the same maximum titer 
level.  
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Werkstetter - ProCeDE supplementary manuscript - Submission Gastroenterology 10 Mar 2017  21 
 
Table S1: Specifications of Local TGA-IgA and DGP-IgG 
Table S1: Specifications of local TGA-IgA and DGP-IgG tests (as applied in and reported by the laboratories of the clinical centers), including manufacturer and test-kit, applied 
limits of normal, maximum measuring range (if any) and information if calibration curves were available or not 
manufacturer name of test-kit 
settings values 
assigned to 
samples above 
the maximum 
of measuring 
range (if any) 
Calibration 
curve 
(yes/no) 
 
number of 
centers 
using the 
same test 
and settings 
unit 
limit of 
normal 
limit of 
normal 
(upper, if 
any range) 
TGA-IgA tests 
Biosystems, S.A. Anti-Tranglutaminase IgA U/ml <10 >14 >100  unknown 1 
Delta BiologicalsDIA Medix Anti-Tissue Transglutaminase IgA U/ml <1 >7 >200  yes 1 
EUROIMMUN Polska  recombinant, expression with baculovirus vector in insect cells U/ml <20 ≥20 >200 unknown 1 
EUROIMMUN AG Anti-Tissue Transglutaminase ELISA (IgA)   RU/ml <20 ≥20 >200 yes 1 
 
Anti-Gewebs-Transglutaminase ELISA (IgA)   U/ml <8 >=12 none yes 1 
Eurospital 
Eu-tTG 
U/ml <7 >16 none yes 1 
 U/ml <9 >=16 >100 yes 5 
in house ultra-sensitive liquid-phase capture RBC ELISA U/ml <3 >=5 >100 yes 1 
in house Radioligand assay cpm <150 cpm >=150 4000 no 1 
Inova Diagnostics Quanta Lite h-tTGIgA U <20 >=20 N/A no 3 
Phadia-Thermofisher Varelisa-Celikey U/ml <5 >8    >100 yes 1 
 
EliA Celikey IgA ImmunoCAP  
 
U/mL <4 >10 >100 yes 1 
 U/ml <6 >6 >128 yes 1 
 
U/ml <7 >=10 >128 yes 13 
DGP-IgG tests 
EUROIMMUN AG Anti-Gliadin-(GAF3X) ELISA (IgG) RU/ml <25 --- none yes 2 
Inova Diagnostics QUANTA LiteTM Gliadin IgG II U/ml 20 30 none no 4 
Phadia EliA Giadin DP IgG ImmunoCAP U/ml 7 10 >100 / none yes 5 
Orgentec Anti-DGP IgG U/ml 8 12 none unknown 1 
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Table S2: Specifications of Local EMA-IgA 
 
Table S2: Specifications of local EMA tests as applied in and indicated by the laboratories of the clinical centers, including name of manufactuerer and test kit, 
type of result (titration to lowest dilution or ordinal scale) and lowest dilution regarded positive if titration to lowest dilution was done 
manufacturer Name of test-kit 
Type of result  
(titration to highest dilution, e.g. 
1:10, OR ordinal scale, e.g. 
"negative", "mild pos.", "pos." OR 
"+" "++" "+++") 
lowest dilution 
regarded as 
positive 
number of 
centers using 
the same test 
and settings 
Alphadia Immunofluorescence ordinal scale na 3 
Bio-Diagnostics NOVA Lite Monkey Oesophagus IFA KIT EMA-IgA and IgG ordinal scale na 1 
BioSystems Monkey Oesophagus EMA-IgA and -IgG titration  ≥1:5 1 
Delta BiologicalsDIA Medix Primate Distal Esophagus Kit EMA-IgA and -IgG ordinal scale na 1 
EUROIMMUN AG Monkey Oesophagus EMA-IgA and -IgG titration  ≥ 1:10 5 
Eurospital Antiendomysium IgA and IgG Monkey Oesophagus ordinal scale na 4 
 NOVA Lite Monkey Oesophagus IFA KIT EMA-IgA and IgG 
 
titration  ≥ 1:5 1 
Inova Diagnostics titration  ≥ 1:10 4 
 ordinal scale na 5 
IMMCO Diagnostics EMA IgA and IgG titration  na 1 
In house EMA IgA and IgG titration  1:2.5 1 
In house EMA IgA and IgG ordinal scale na 1 
In-house EMA IgA and IgG ordinal scale na 1 
Scimedx EMA-IgA ordinal scale na 2 
Orgentec Monkey Oesophagus EMA-IgA and -IgG titration  ≥ 1:5 1 
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Table S3: Specifications of central ELISA based tests (TGA, DGP) 
 
  
Table S3: Specifications of centrally analysed TGA-IgA/IgG and DGP-IgG ELISA tests; all these tests were run on the same automatized platform (Euroimmun 
Analyzer I) and processed by the same bioanalysts. 
Test Thermofish
er/ Phadia 
Varelisa 
Celikey IgA 
Inova R h-
tTG IgA 
Inova DGP 
IgG 
Eurospital 
tTG IgA 
Eurospital 
Glia Pep 
IgG 
Euroimmun 
tTG IgG 
Euroimmun 
GAF-3X 
Zedira tTG 
IgA closed 
Zedira DGP 
IgG 
Zedira tTG 
IgA open 
Zedira tTG 
IgG open 
REF no. 181 96 704605 704520 9105 9138 EA 1910-
9601 A 
EV 3011-
9601 G 
E001 E020 E006 E007 
Instrument Euroimmun Analyzer I 
Standards 6 standards in 
duplicates 
5 standards in 
duplicates 
1 standard in 
duplicates 
5 standards in 
duplicates 
5 standards in 
duplicates 
3 standards in 
single determ. 
3 standards in 
single determ. 
6 standards in 
duplicates 
6 standards in 
duplicates 
6 standards in 
duplicates 
6 standards in 
duplicates 
Measuring 
range 
0 - 100 U/ml 0 - 100 U/ml 0 - >150 U 0 - 100 AU/ml 0 - 100 AU/ml 2 - 200 RU/ml 2 - 200 RU/ml 0 - 100 U/ml 0 - 100 U/ml 0 - 100 U/ml 0 - 100 U/ml 
Curve 
drawing / 
calculation 
4 parameter 
lin-log 
cubic spline 
lin-log 
ratio Linear 
regression 
Linear 
regression 
point-to-point, 
linear 
point-to-point, 
linear 
4 parameter 
lin-log 
4 parameter 
lin-log 
4 parameter 
lin-log 
4 parameter 
lin-log 
Kit 
controls  
1 pos + 1 neg 
in duplicates 
1 pos + 1 neg 
in duplicates 
1 pos + 1 neg 
in duplicates 
1 pos + 1 neg 
in duplicates 
1 pos + 1 neg 
in duplicates 
1 pos + 1 neg 
in single 
determ. 
1 pos + 1 neg 
in single 
determ. 
1 pos + 1 neg 
in duplicates 
1 pos + 1 neg 
in duplicates 
1 pos + 1 neg 
in duplicates 
1 pos + 1 neg 
in duplicates 
In house 
control 
1 in duplicates 1 in duplicates 1 in duplicates 1 in duplicates 1 in duplicates 1 in single 
determ. 
1 in single 
determ. 
1 in duplicates 1 in duplicates 1 in duplicates 1 in duplicates 
Inter-
assay-
variation, 
validation 
data 
N=9,  
Mean = 10, 
CV% = 14 
N=6, 
Mean = 17, 
CV% = 5 
N=7,  
Mean = 11, 
CV% = 6 
N=5,  
Mean = 25, 
CV% = 9 
N=5,  
Mean = 20, 
CV% = 6 
N=5,  
Mean = 25, 
CV% = 19 
N=5,  
Mean = 23, 
CV% = 7 
N=6,  
Mean = 5, CV% 
= 10 
N=6,  
Mean = 2, CV% 
= 22 
N=6,  
Mean = 5, CV% 
= 10 
N=6,  
Mean = 16, 
CV% = 8 
N=6,  
Mean = 55, 
CV% = 12 
N=6,  
Mean = 79, 
CV% = 9 
N=6,  
Mean = 64, 
CV% = 6 
N=5,  
Mean = 85, 
CV% = 5 
N=5,  
Mean = 80, 
CV% = 8 
N=5, 
Mean = 115, 
CV% = 4 
N=5,  
Mean = 101, 
CV% = 4 
N=5,  
Mean = 64, 
CV% = 8 
N=6,  
Mean = 48, 
CV% = 4 
N=5,  
Mean = 51, 
CV% = 3 
N=5,  
Mean = 50, 
CV% = 4 
Intra-
assay-
variation, 
validation 
data 
N=4,  
Mean = 10, 
CV% = 13 
N=4,  
Mean = 15, 
CV% = 9 
N=6,  
Mean = 11, 
CV% = 5 
N=5,  
Mean = 20, 
CV% = 6 
N=5,  
Mean = 29, 
CV% = 4 
N=5,  
Mean = 29, 
CV% = 5 
N=5,  
Mean = 20, 
CV% = 5 
N=4, 
Mean = 5, CV% 
= 11 
N=4,  
Mean = 3, CV% 
= 18 
N=4,  
Mean = 6, CV% 
= 10 
N=4,  
Mean = 15, 
CV% = 5 
N=4,  
Mean = 58, 
CV% = 17 
N=4,  
Mean = 67, 
CV% = 16 
N=4,  
Mean = 68, 
CV% = 6 
N=5,  
Mean = 86, 
CV% = 3 
N=5,  
Mean = 87, 
CV% = 3 
N=5,  
Mean = 105, 
CV% = 3 
N=5,  
Mean = 79, 
CV% = 6 
N=4,  
Mean = 55, 
CV% = 5 
N=4,  
Mean = 54, 
CV% = 7 
N=4,  
Mean = 49, 
CV% = 8 
N=4,  
Mean = 45, 
CV% = 5 
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Table S4: Specifications of central non-ELISA tests (TGA, DGP) 
 
Table S4: Specification of the four centrally analysed non-ELISA-based TGA-IgA and DGP-IgG tests from 
Thermofisher/Phadia and Inova Diagnostics; the tests were run on the specific instruments 
 
Test Thermofisher/Phadia 
EliA Celikey DGP IgG 
Thermofisher/Phadia 
EliA Celikey tTG IgA 
QUANTA Flash t-TG 
IgA 
QUANTA Flash DGP 
IgG 
REF no.  na  na 701103 701173 
Instrument Phadia250 Phadia250 BIO-FLASH BIO-FLASH 
Standards 6 standards in duplicates 6 standards in duplicates *lot-specific calibration *lot-specific calibration 
Measuring 
range 
0 - 600 µg/l 0 - 80 µg/l 1,9 CU - 4965,5 CU 2,8 CU - 1936,7 CU 
Curve drawing / 
calculation 
Rodbard 4-parameter Rodbard 4-parameter lot specific working calibration curve 
lot specific working 
calibration curve 
Kit controls  1 pos + 1 neg in single determ. + 1 curve control 
1 pos + 1 neg in single 
determ. + 1 curve control 1 pos + 1 neg 1 pos + 1 neg 
In house control 1 in single determ. 1 in single determ. - - 
Inter-assay-
variation, 
validation data 
N=5, Mean = 19, CV% = 6 N=5, Mean = 13, CV% = 4 N=6, Mean = 10, CV% = 6 N=6, Mean = 11, CV% = 7 
N=5, Mean = 190, CV% = 4 N=5, Mean = 123, CV% = 6 N=6, Mean = 67, CV% = 5 N=6, Mean = 56, CV% = 2 
Intra-assay-
variation, 
validation data 
N=4, Mean = 20, CV% = 0 N=4, Mean = 13, CV% = 5 N=3, Mean = 10, CV% = 4 N=3, Mean = 11, CV% = 5 
N=4, Mean = 199, CV% = 6 N=4, Mean = 127, CV% = 6 N=3, Mean = 67, CV% = 4 N=3, Mean = 56, CV% = 1 
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Table S5: Summary of recruited but excluded patients including reasons for exclusion 
 
Table S5: Summary of recruited but excluded patients including reasons for exclusion and sorted by time of 
exclusion (n=79); patients which have been excluded due to low total IgA are listed separately in table S8 
(n=17), in total 96 recruited patients had to be excluded. Some patients listed below have not been entered 
into the database and therefore have no ID (n=21; 
ID Time of exclusion Reason for exclusion 
not in database* after recruitment withdrew consent for study 
not in database* after recruitment withdrew consent for study 
not in database* after recruitment withdrew consent for study 
not in database* after recruitment withdrew consent for study 
not in database* after recruitment withdrew consent for biopsy 
not in database* after recruitment withdrew consent for biopsy 
not in database* after recruitment withdrew consent for biopsy 
not in database* after recruitment withdrew consent for biopsy 
not in database* after recruitment withdrew consent for biopsy 
not in database* after recruitment withdrew consent for biopsy 
not in database* after recruitment withdrew consent for biopsy 
not in database* after recruitment withdrew consent for biopsy 
not in database* after recruitment violation of exclusion criteria "immunodeficiency" 
not in database* after recruitment violation of exclusion criteria "previous CD diagnosis" 
not in database* after recruitment violation of exclusion criteria "previous CD diagnosis" 
1017 after recruitment incomplete - no histology slides available 
151 after recruitment incomplete - no HLA-typing (neither central nor local) 
182 after recruitment incomplete - no HLA-typing (neither central nor local) 
203 after recruitment incomplete - no HLA-typing (neither central nor local) 
205 after recruitment incomplete - no HLA-typing (neither central nor local) 
241 after recruitment incomplete - no HLA-typing (neither central nor local) 
273 after recruitment incomplete - no HLA-typing (neither central nor local) 
326 after recruitment incomplete - no HLA-typing (neither central nor local) 
1005 after recruitment incomplete - no HLA-typing (neither central nor local) 
832 after recruitment incomplete - no serum sample 
973 after recruitment incomplete - no serum sample 
45 after recruitment incomplete - several samples/data missing 
623 after recruitment incomplete - several samples/data missing 
954 after recruitment incomplete - several samples/data missing 
955 after recruitment incomplete - several samples/data missing 
956 after recruitment incomplete - several samples/data missing 
957 after recruitment incomplete - several samples/data missing 
958 after recruitment incomplete - several samples/data missing 
not in database* after recruitment incomplete - several samples/data missing 
not in database* after recruitment incomplete - several samples/data missing 
not in database* after recruitment incomplete - several samples/data missing 
not in database* after recruitment incomplete - several samples/data missing 
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not in database* after recruitment incomplete - several samples/data missing 
not in database* after recruitment incomplete - several samples/data missing 
162 after reference pathology non evaluable histology  
209 after reference pathology non evaluable histology  
398 after reference pathology non evaluable histology  
414 after reference pathology non evaluable histology  
465 after reference pathology non evaluable histology  
478 after reference pathology non evaluable histology  
571 After reference pathology non evaluable histology  
679 after reference pathology non evaluable histology  
817 after reference pathology non evaluable histology  
885 after reference pathology non evaluable histology  
1021 after reference pathology non evaluable histology  
66 after 4th review non evaluable histology 
88 after 4th review non evaluable histology 
90 after 4th review non evaluable histology 
116 after 4th review non evaluable histology 
181 after 4th review non evaluable histology 
192 after 4th review non evaluable histology 
221 after 4th review non evaluable histology 
224 after 4th review non evaluable histology 
267 after 4th review non evaluable histology 
384 after 4th review non evaluable histology 
437 after 4th review non evaluable histology 
489 after 4th review non evaluable histology 
516 after 4th review non evaluable histology 
598 after 4th review non evaluable histology 
628 after 4th review non evaluable histology 
638 after 4th review non evaluable histology 
648 after 4th review non evaluable histology 
655 after 4th review non evaluable histology 
698 after 4th review non evaluable histology 
703 after 4th review non evaluable histology 
740 after 4th review non evaluable histology 
755 after 4th review non evaluable histology 
844 after 4th review non evaluable histology 
875 after 4th review non evaluable histology 
944 after 4th review non evaluable histology 
729 4th review protocol violation – gluten-free diet at time of biopsy is confirmed 
541 4th review 
protocol violation – negative TGA- and EMA-IgA, inclusion was based 
on positive TGA-IgG only and no total IgA had been done in the local 
center, but in the central lab IgA deficiency was excluded 
733 4th review technical error - sample mix-up is very likely 
840 4th review technical error - sample mix-up (confirmed for DNA, likely for serum) 
* for patients who were only submitted via the pre-screening log but no entered into the database, only basic information on age, 
gender TGA-IgA is available 
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Table S6: Excluded patients compared to the patients in the final cohort 
 
 Table S6: Excluded patients (except patients in low total IgA group) compared to patients in the final 
cohort for gender, age and the x-fold ULN of TGA-IgA 
 
Basic characteristics 
Excluded patients 
(except low total IgA) 
(N=79) 
Patients included in final cohort 
(N=707) 
Female [%] 59.7% 65.1% 
Age [yrs] mean ± SD (median; min-max) 6.3±4.4 (4.3; 1.1-17.9) 7.1±4.2 (6.2;0.7-18.6) 
TGA-IgA x-fold ULN mean ± SD (median; 
min-max)* 
23.9±120.4 (5.3;0.0-
1018.3) 25.8±61.8 (11.8; 0.0-985.8) 
*please note: some local laboratories only measured up to a certain maximum measuring range 
 
Table S7: Gastrointestinal and extraintestinal symptoms 
 
Table S7: Gastrointestinal and extraintenstinal symptoms associated with celiac disease which were 
present within 4 weeks prior to study visit, listed according to frequency in descending order. 
Symptom Number of patients (%) Total number of patients 
(N) 
Gastrointestinal symptoms 
Abdominal pain* 355 (50.6) 
701 
- mild  161 (22.9) 
- moderate 132 (18.8) 
- severe 34 (4.9) 
- child cannot describe 28 (4.0) 
Diarrhea# 190 (27.1) 702 
Abdominal distention 179 (25.3) 707 
Flatulence 127 (18.2) 698 
Constipation§ 116 (16.5) 703 
Recurrent vomiting 61 (8.7) 704 
Extraintestinal symptoms 
Weight loss or insufficient gain+  213 (30.7) 693 
Growth retardation+ 113 (16.5) 684 
Anemia 117 (16.6) 686 
Anorexia  127 (18.19) 698 
Fatigue / lack of energy 159 (22.8) 696 
Irritability / moodiness 168 (24.2) 694 
Lack of concentration (in children 
≥6yrs of age) 49 (10.2) 481 
Delayed puberty (in adolescents 
≥12yrs of age) 7 (2.0) 343 
Amenorrhea (in girls post-menarche) 5 (1.8) 277 
*severity of abdominal pain was assessed as follows: mild = no influence on daily activity; moderate = some influence on daily 
activity, e.g. child interrupts play or homework; severe = major influence on daily activity 
#chronic or intermittent 
§only one stool every 3 days  / less than 3 stools per week 
+ decrease of at least 2 percentiles 
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Table S8: Characteristics of patients with low total IgA 
Table S8: Characteristics of patients with low total IgA, both from local and from central laboratories and pathologists, including basic characteristics, local and central 
serology outcomes and histopathology (Marsh staging) as well as symptoms and final central diagnosis 
ID Gender Age [yrs] 
HLA risk 
group 
Total 
IgA [g/l] 
Local TGA-
IgA [x-fold 
above ULN] 
Local TGA-
IgG [x-fold 
above ULN] 
No. of 
positive 
TGA-IgA in 
central lab 
Local DGP-
IgG [x-fold    
above ULN] 
No. of 
positive 
DGP-IgG in 
central lab 
Local 
EMA-IgA 
Local 
EMA-IgG 
Central 
EMA-IgG 
Local 
histology 
Marsh 
staging 
Reference 
histology 
Marsh 
staging 
Symptoms 
Final  
central 
diagnosis 
5 male 17.1 1 0.06 0.22 4.1 1/8 - 6/6 negative 1:20 1:1000 M3 M3 none proven CD 
187 male 3.9 5 0.02 0.00 - 0/8 - 0/6 negative - negative M0 M1 diarrhea no CD 
429 male 4.2 1 0.08 0.22 - 0/8 13.3 6/6 - - 1:1000 M3 M3 diarrhea, flatulence, fatigue 
proven CD 
451 female 12.5 3 0.08 0.22 - 0/8 6.0 6/6 - - 1:1000 M3 M3 severe abd. pain, fatigue, amenhorrea 
proven CD 
592 female 13.5 1 0.06 0.00 4.8 0/8 4.3 6/6 negative positive 1:1000 M3 M3 constipation, weight loss, growth failure 
proven CD 
621 female 3.2 2 0.06 0.00 5.0 0/8 - 6/6 negative 1:1280 1:1000 M3 M3 diarrhea, growth failure, weight loss 
proven CD 
649 female 6.4 5 0.00 0.00 2.3 0/8 - 0/6 - negative negative M0 M1 abd. pain, diarrhea no CD 
727 female 6.0 3 0.06 - 75.4 0/8 - 6/6 - positive 1:1000 M3 M3 diarrhea, fatigue proven CD 
816 male 2.7 5 0.09 - 2.9 0/8 - 5/6 - - negative M0 M0 abd. pain, diarrhea, anorexia, weight loss no CD 
912 male 5.2 4 0.06 0.57 8.1 1/8 - 5/6 negative weakly positive negative M3 M3 abd. pain, diarrhea proven CD 
918 male 2.6 3 0.06 0.00 5.6 0/8 - 0/6 negative - negative M0 M3 abd. distention no CD 
924 male 1.0 5 0.12 0.14 1.3 0/8 - 5/6 negative - negative M0 M0 diarrhea, anorexia no CD  
941 male 7.0 1 0.6 - 65.6 0/8 0.2 2/6 - 1:640 1:1000 M2 M3 diarrhea proven CD 
945 male 6.2 3 0.6 - 27.1 0/8 - 6/6 - 1:320 1:1000 M2 M3 irritability proven CD 
992 female 14.6 3 0.7 0.01 - 0/8 - 4/6 positive - 1:1000 M0 M0 abd. pain, diarrhea, constipation, vomiting 
Inconclusive
/potential 
994 female 13.2 1 0.7 - 18.29 0/8 - 6/6 negative - 1:1000 M3 M3 abd. pain, diarrhea, constipation 
proven CD 
1023 female 3.3 1 0.23 0.01 10.0 0/8 - 6/6 negative positive 1:1000 M3 M3 fatigue proven CD 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Werkstetter - ProCeDE supplementary manuscript - Submission Gastroenterology 10 Mar 2017  29 
 
Table S9: Characteristics of patients with negative TGA-IgA at time of biopsy 
  Table S9: Characteristics of patients with negative TGA-IgA at time of biopsy but previously positive TGA-IgA in external laboratory which lead to referral to clinical center and biopsy 
ID Gender Age 
Gluten-
free diet 
prior to 
biopsy? 
Gluten 
intake 
HLA risk 
group 
Total 
IgA [g/l] 
Initial 
TGA-IgA# 
Cut-off 
initial 
TGA-IgA 
testkit 
Local TGA-
IgA [x-fold 
above ULN] 
No. of 
positive 
TGA-IgA in 
central lab 
No. of 
positive 
DGP-IgG in 
central lab 
Local 
EMA-IgA 
Central 
EMA-Iga 
Local 
pathology 
Reference 
pathology Risk for CD and/or symptoms 
Final 
central 
diagnosis 
55 female 12.5 no  daily  1 1.05 14 U/l < 7 U/ml 0.4 1/8 5/6 negative 1:5 M0  M0 type 1 diabetes, 1st degree relative no CD 
124 female 5.6 yes*  daily  3 0.53 31 <9 U/ml 0.77 5/8 4/6 1:10 1:5 M3 only in bulb M0 abd. pain, diarrhea, vomiting proven CD 
129 female 6.1 no  daily  5 1.10 28.7 - 0.2 0/8 1/6 - negative M0  M0 growth failure, abd. distention no CD 
236 male  9.3 no  daily  5 0.81 “positive” - 0.9 8/8 5/6 positive 1:100 M3 M3 severe abd. pain proven CD 
237 male  5.3 no  daily  5 1.06 “positive” - 0.9 3/8 0/6 negative negative M0  M0 none no CD 
239 female 3.2 no  daily  4 0.65 “positive” - 0.2 0/8 0/6 negative negative M0  M0 abd. distention no CD 
277 female 6.0 no  3-4x/week 3 1.45 “positive” - 0.7 6/8 1/6 1:5 1:10 M0  M2 1st degree relative; abd. pain Inconclusive 
286 female 4.5 no  daily  4 0.96 “positive” - 0.5 6/8 4/6 mild pos 1:10 M3 only in bulb M0 abd. pain, diarrhea, weight loss proven CD 
288 male  6.7 yes*  daily  5 0.92 “positive” - 0.1 0/8 0/6 negative negative M0  M0 abd. pain, diarrhea no CD 
298 female 4.7 no  daily  3 0.54 29 U/ml <20 U/ml 0.4 0/8 0/6 negative negative M0  M0 abd . pain no CD 
301 male  5.3 no  daily  5 1.68 49 U/ml <20 U/ml 0.4 0/8 2/6 negative negative M0  M0 abd. pain no CD 
364 female 10.8 no  daily  1 1.48 5.3 U/ml <5 U/ml 0.8 6/8 6/6 ++ 1:100 M3 M3 none proven CD 
394 female 9.3 no daily 5 1.36 34.9 U/ml <18 U/ml 0.0 0/8 0/6 negative negative M0 M0 autoimmune thyroid disease; abd. pain, weight loss, growth failure no CD 
408 female 6.8 no  daily  3 1.84 24 U/ml <20 U/ml 0.0 0/8 0/6 negative negative M0 M0 severe abd. pain no CD 
409 female 10.5 no  daily  5 1.03 24 U/ml <20 U/ml 0.0 0/8 0/6 negative negative M0 M0 severe abd. pain, abd. distention no CD 
428 female 1.06 no  daily  5 0.27 26 U/ml <18 U/ml 0.0 0/8 5/6 negative negative M3 M0 weight loss, growth failure no CD 
433 female 7.1 no  daily  5 1.73 23.2 U/ml <18 U/ml 0.0 0/8 0/6 negative negative M1  M1 none no CD 
459 female 2.2 no  daily  3 0.48 35 U/ml <20 U/ml 0.0 0/8 1/6 negative negative M0  M0 abd. pain, diarrhea, vomiting no CD 
493 female 7.2 no  daily  5 0.55 33.8 U/ml <7 U/ml 0.0 0/8 0/6 - negative M0  M3 abd. pain, diarrhea, fatigue no CD 
524 male  14.9 no  daily  5 4.04 23 U/ml 20 U/ml 0.0 0/8 0/6 negative negative M0  M1 abd. pain no CD 
642 female 3.3 no  3-4x/week 3 0.33 7 U/l <7 U/ml 0.6 1/8 0/6 negative negative M0 M1 abd. pain, diarrhea, constipation no CD 
651 female 13.3 no  3-4x/week 3 1.21 8.9 U/ml <7 U/ml 0.9 8/8 6/6 1:200 1:100 M3 M2 abd. pain, weight loss, fatigue proven CD 
659 female 4.2 no  daily  3 0.57 “positive” - 0.8 3/8 2/6 negative 1:10 M0 M2 abd. pain proven CD 
667 male  10.2 no  daily  3 0.72 “positive” - 0.4 1/8 2/6 1:5 1:10 M0  M1 abd. pain proven CD 
732 female 2.7 no  daily  3 0.97 17 U/ml <7 U/ml 0.1 8/8 6/6 1:2560 1:10 M0 M3 diarrhea proven CD 
747 female 5.5 no  daily  3 0.40 9.1 U/ml <9 U/ml 0.4 4/8 6/6 ++ 1:10 M2 M1 none proven CD 
757 female 14.3 no  daily  5 1.07 60 U/ml <20 U/ml 0.1 1/8 0/6 negative negative M0  M1 none no CD 
1022 female 12.9 no  daily  3 1.29 “positive” - 0.4 2/8 1/6  negative M0  M0 type 1 diabetes no CD 
1025 male  3.7 no  daily  1 0.23 “positive” - 0.0 0/8 1/6  negative M0  M0 growth failure, 1
st degree relative no CD 
* patient 124 was on tentative gluten-free diet for 2 weeks, diet was stopped 11 months prior to biopsy; patient 288 was on gluten-free diet for 6 months, diet was stopped 7 months prior to biopsy;  
# initial TGA-IgA was initially done in the clinical center or elsewhere (pediatric practice or another hospital) and the patient was forwarded to the clinical center due to the positive TGA-IgA result 
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Table S10: Characteristics of patients with initially negative HLA risk alleles 
Table S10: Characteristics of 18 patients with initially negative HLA risk alleles, thereof two with 3rd typing due to clinical suspicion of CD, and 16 patients in which CD 
was clearly excluded (N=707); basic characteristics, details on HLA-typing, local and central serology and histology (Marsh staging), symptoms and final diagnosis 
ID Age [yrs] 
Gender 
 
HLA-DQ 
genotype 
Eurospital 
Positive alleles 
HLA-DQ genotype 
EUROIMMUN 
Positive alleles 
3rd typing  
(SNPs) 
Total IgA 
[g/l] 
Local TGA-
IgA [x-fold 
above 
ULN] 
No. of 
positive 
TGA-IgA in 
central lab 
No. of 
positive 
DGP-IgG in 
central lab 
Local 
EMA-IgA 
Central 
EMA-IgA 
Marsh staging of 
pathologists Symptoms 
Final  
central 
diagnosis Local Reference 
507 1.8 male DQA1*05 α-subunit DQ2.5 DQ2.2/DQ7$ 1.06 33.3 8/8 6/6 1:320 1:1000 M3 M3 diarrhea, weight loss, anorexia 
proven 
CD 
761 1.5 female rare allele combination# α-subunit DQ2.2 
DQ9/variant 
DQ2.2# 1.55 1.3 8/8 6/6 1:1280 1:000 M3 M3 
diarrhea, weight loss, 
vomiting, anorexia 
proven 
CD 
237 5.3 male DQA1*05 α-subunit DQ2.5 - 1.06 0.85 3/8 0/6 negative negative M0 M0 none no CD 
211 1.5 male all negative all negative - 0.53 1.05 0/8 0/6 negative negative M0 M0 diarrhea, growth retardation no CD 
829 4.6 female DQA1*05 α-subunit DQ2.5 - 0.43 1.30 0/8 2/6 negative negative M0 M0 abd. pain, weight loss, growth failure no CD 
301 5.3 male DQA1*05 α-subunit DQ2.5 - 1.68 0.44 0/8 2/6 negative negative M0 M0 abd. pain no CD 
412 15.7 female DQA1*05 α-subunit DQ2.5 - 1.84 1.50 0/8 0/6 negative negative M0 M0 abd. pain no CD 
839 1.3 male DQA1*05 α-subunit DQ2.5 - 0.25 2.65 0/8 0/6 negative negative M0 M2 Flatulence, anorexia no CD 
757 14.4 female all negative all negative - 1.07 0.04 1/8 0/6 negative negative M0 M1 abd. pain no CD 
493 7.1 female all negative all negative - 0.55 0.01 0/8 0/6 negative negative M0 M3A abd. pain, diarrhea, no CD 
213 5.7 male all negative α-subunit DQ8 A1*03:01 
- 1.06 1.24 1/8 0/6 negative negative M3 M0 recurrent arthritis no CD 
355 8.0 female DQA1*05 α-subunit DQ2.5 - 1.11 2.45 0/8 1/6 negative negative M1 M0 abd. distention no CD 
766 14.9 male all negative α-subunit DQ8 A1*03:02/03 
- 1.64 2.95 0/8 1/6 negative negative M1 M0 abd. pain, growth retardation, no CD 
394 9.3 female all negative all negative 
- 
1.36 0.03 0/8 0/6 negative negative M0 M0 
abd. pain, weight loss, 
constipation, growth 
failure 
no CD 
838 3.1 female DQA1*05 α-subunit DQ2.5 - 0.51 1.90 0/8 0/6 negative negative M0 M1 anorexia, weight loss, growth failure no CD 
128 11.4 female DQA1*05 α-subunit DQ2.5 - 2.43 1.65 3/8 1/6 negative negative M1 M0 constipation, growth failure, irritability no CD 
288 6.7 male DQA1*05 α-subunit DQ2.5 - 0.92 0.13 0/8 0/6 negative negative M0 M0 abd. pain, abd. distention, diarrhea no CD 
130 1.1 male all negative all negative - 0.37 1.64 0/8 0/6 negative negative M3 M0 constipation, irritability no CD 
$ mix-up of initial sample with sample of the child’s father was proven; 3rd typing was done with new sample and the result was confirmed by re-typing with EU-Gen-risk and EUROarray 
# Eurospital found DRB1*07 DRB1*04, DQA1*0201 DQA1*03, DQB1*0303/01, SNP typing and DQB1*03 subtyping in University of Debrecen showed DQ9 (DQA1*03-DQB1*0303) and a rare allele DR7-
DQA1*0201-B1*0303/01  
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Table S11: Characteristics of inconclusive patients 
  Table S11: Characteristics of the 16 patients that were finally considered to be inconclusive (N=707), including final voting outcome of the diagnostic committee 
ID Gender Age 
Gluten-
free diet 
prior to 
biopsy? 
Gluten 
intake 
HLA 
risk 
group 
Total 
IgA  
[g/l] 
Local 
TGA-IgA 
[x-fold 
above 
ULN] 
No. of 
positive 
TGA-IgA 
in central 
lab 
No. of 
positive 
DGP-IgG 
in central 
lab 
Local EMA-
IgA 
Central 
EMA-IgA 
Marsh staging of 
pathologist 
Morphometry 
analysis: 
Villous-crypt-
ratio 
Symptoms or at risk 
for CD 
Final voting 
of the 
diagnostic 
committee 
(6 voters) 
Reason why the 
case remained 
inconclusive 
Local Reference 
1 2 
22 male 2.6 no daily 3 0.32 1.5 8/8 6/6 positive positive M0 M0 M0 2.08 but only 2 units measurable fatigue, irritability potential (6) no villous atrophy 
115 female 7.0 no daily 3 1.94 10.0 1/8 0/6 1:10 negative M0 M0 - 1.25; villous atrophy in bulb 
T1DM; abd. pain, 
constipation 
(5) potential 
(1) 
inconsistent serology 
& histology 
190 male 9.8 no daily 3 0.98 4.7 4/8 2/6 mild positive negative M1 M1 M2 1:4; patchy 1st degree relative unclear (3) proven (3) 
inconsistent serology 
& histology 
201 male 15.6 no daily 1 1.79 5.1 7/8 6/6 mild positive positive M0 M1 M1 2.9; normal none potential (6) o villous atrophy 
240 female 1.1 no daily 3 1.16* 20.0 0/8 4/6 negative negative M3 M3 M3 0.3; clear atrophy diarrhea, weight loss, rowth retardation, 
unclear (3) 
proven CD (3) 
negative EMA and 
central serology 
255 male 3.7 no daily 1 0.42 1.5 2/8 4/6 negative negative M0 M0 M0 Not measurable abdominal pain, vomiting 
potential (5) 
exclude (1) 
Inconsistent serology 
& histology 
268 female 11.7 no daily 3 2.11 2.9 7/8 1/6 negative negative 
pathologic 
but no 
Celiac 
M0 - 2.3, but only 1 unit measurable 
T1DM, autoim. thyroid 
disease;  
abd. pain 
potential (6) 
positive TGA but 
negative EMA, no 
villous atrophy 
277 female 6.0 no 3-4x /week 3 1.45 0.7 6/8 1/6 1:5 positive M0 M2 M0 2.19; normal 1
st degree relative,; 
abd. pain 
potential (5) 
proven CD (1) 
inconsistent serology 
& histology 
370 male 3.9 no daily 3 0.27 1.9 0/8 0/6 + negative M3 M3 M3 0.53; villous atrophy 
abd. pain, anorexia, 
weight loss 
unclear (4) 
proven (2) 
negative central 
serology 
498 female 4.6 no* daily 2 1.03 5.2 7/8 5/6 1:10 positive M3 M0 M2 2.2; normal growth retardation potential (6) inconsistent histology 
518 female 8.3 no daily 5 1.05 12.3 4/8 3/6 1:2.5 negative M0 M0 - 2.9; normal none potential (6) inconsistent serology & no villous atrophy 
520 male 2.7 no daily 3 0.70 5.5 7/8 3/6 negative positive M0 M1 M1 2.2 but only 2 units measurable weight loss potential (6) no villous atrophy 
644 male 5.1 no daily 3 0.62 3.4 7/8 4/6 + positive M1 M1 M3 2.5, normal on measurable sites abdominal pain 
potential (3) 
proven CD (3) inconsistent histology 
777 female 5.2 no daily 3 1.87 3.0 6/8 0/6 negative negative M0 M0 - 1.78 signs of crypt hyperplasia 
type 1 diabetes; abd. 
pain, anorexia, irritability 
potential (5) 
proven CD (1) no villous atrophy 
813 female 3.2 no 3-4x /week 2 0.55 2.2 7/8 4/6 1:2.5 positive M1 M1 - 2.3; normal none potential (6) no villous atrophy 
831 female 6.0 no daily 3 1.12 2.7 5/8 2/6 negative positive M0 M3 M3 Not measurable abd. pain, anorexia, weight loss 
proven CD (3) 
unclear (2) 
potential (1) 
inconsistent serology 
& histology 
*suspicion of wrong total IgA value (low total low total IgA as explanation) not confirmed by the center clinical center; no serum was left after central serology was done, and no follow-up available. 
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Table S12: Characteristics of false positive patients 
 
Table S12: Characteristics of false positive patients, either for local TGA-IgA ≥10fold ULN or for central TGA-IgA / DGP-IgG ≥10fold ULN; 
ID gender age 
HLA 
risk 
group 
Total 
IgA  
[g/l] 
Local TGA-
IgA [x-fold 
above ULN] 
No. of 
positive 
TGA-IgA in 
central lab 
No. of 
positive 
DGP-IgG in 
central lab 
Local 
EMA-IgA 
Central 
EMA-IgA 
Marsh staging of pathologist Morphometry 
analysis: 
Villous-crypt-ratio 
Risk factors or 
symptoms indicative 
for CD 
Final 
diagnosis 
Name of false positive 
local TGA-IgA or 
central TGA/DGP test 
≥10xULN  
Local Reference 
1 
Reference 
2 
115 female 7.0 3 1.94 10.0 1/8 0/6 1:10 negative M0 M0 - 1.25; villous atrophy in bulb 
type 1 diabetes; 
moderate abdominal 
pain, constipation 
Inconclusive 
case 
local TGA-IgA:  
Euroimmun Polska 
(recombinant expression 
with baculovirus vector in 
insect cells), limit of 
normal <20 U/ml 
240* female 1.1 3 1.16# 20.0 0/8 4/6 negative negative M3 M3 M3 0.3; clear atrophy 
diarrhea, weight loss, 
growth failure, abdominal 
distention 
Inconclusive 
case 
local TGA-IgA:  
done in external lab, test 
unknown, limit of normal 
<15 U/ml 
518 female 8.3 1 1.05 12.3 4/8 3/6 1:2.5 negative M0 M0 - 2.9, normal none Inconclusive case 
local TGA-IgA: 
home-made RBC ELISA, 
limit of normal < 3 U/ml 
796 male 6.9 3 1.15 10.3 2/8 0/6 negative negative M0 M0 - - type 1 diabetes; abdominal distention no CD 
local TGA-IgA:  
In-house radioligand 
assay, limit of normal 
<150cpm 
22 male 2.7 3 0.32 1.5 8/8 6/6 positive 1:10 M0 M0 M0 2.08, but only 2 units measurable fatigue, irritability 
Inconclusive 
case 
central test T4: 
  Quanta Flash TG2-IgA 
268 female 11.7 3 2.11 2.9 7/8 1/6 negative 1:10 M0 M0 - 2.3; but only 1 unit measurable 
type 1 diabetes, 
autoimmune thyroid 
disease; mild abdominal 
pain, flatulence 
Inconclusive 
case 
central test T6: 
Euroimmun Anti-TG2-IgA 
644* female 5.1 3 0.62 3.4 7/8 4/6 positive 1:10 M1 M1 M3 2.5, normal on measurable sites mild abdominal pain 
Inconclusive 
case 
central test T6: 
Euroimmun Anti-TG2-IgA 
1022 female 12.9 3 1.29 0.4 2/8 1/6 not available negative M0 M0 - - type 1 diabetes no CD 
central test D1: 
Thermofisher EliA Gliadin 
DGP IgG 
*time gap between local TGA-IgA and biopsy was >14 days: for patient with ID 240, the gap was 16 days, for patient with ID 644 the gap was 54 days.  
#suspicion of wrong total IgA value (low total low total IgA as explanation) not confirmed by the center clinical center; no serum was left after central serology was done, and no follow-up available. 
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Table S13: Diagnostic accuracies measures for central TGA tests 
Table S13: Diagnostic accuracies measures and 95% CI for central TGA tests T1 toT9 ≥10xULN ± combinations with EMA and/or symptoms to diagnose CD 
without biopsy , either considering inconclusive cases as no CD (Method M1, N=696-707) or excluding inconclusive cases (M2, N=680-691); 
Test M N Combination  TP FP FN TN False % Sensitivity§ % [95%CI] Specificity % [95%CI] PPV % [95%CI] LR+ [95%CI] 
T1 M1 707 TGA-IgA ≥10xULN 424 0 221 62 31.26 65.74 61.931 69.40 100.00 94.22 100.00 100.00 96.84 100.00 ∞ ∞ ∞ 
T1 M1 707 + any symptoms 382 0 263 62 37.20 59.23 55.32 63.05 100.00 94.22 100.00 100.00 99.12 100.00 ∞ ∞ ∞ 
T1 M1 707 + malabsorption 261 0 384 62 54.31 40.47 36.65 44.37 100.00 94.22 100.00 100.00 99.02 100.00 ∞ ∞ ∞ 
T1 M1 707 TGA-IgA + EMA-IgA 415 0 230 62 32.53 64.34 60.51 68.04 100.00 94.22 100.00 100.00 96.84 100.00 ∞ ∞ ∞ 
T1 M1 707 + any symptoms 374 0 271 62 38.33 57.98 54.07 61.83 100.00 94.22 100.00 100.00 99.12 100.00 ∞ ∞ ∞ 
T1 M1 707 + malabsorption 255 0 390 62 55.16 39.54 35.74 43.43 100.00 94.22 100.00 100.00 99.02 100.00 ∞ ∞ ∞ 
T1 M2 691 TGA-IgA ≥10xULN 424 0 221 46 31.98 65.74 61.93 69.40 100.00 92.29 100.00 100.00 96.84 100.00 ∞ ∞ ∞ 
T1 M2 691 + any symptoms 382 0 263 46 38.06 59.23 55.32 63.05 100.00 92.29 100.00 100.00 99.12 100.00 ∞ ∞ ∞ 
T1 M2 691 + malabsorption 261 0 384 46 55.57 40.47 36.65 44.37 100.00 92.29 100.00 100.00 99.02 100.00 ∞ ∞ ∞ 
T1 M2 691 TGA-IgA + EMA-IgA 415 0 230 46 33.29 64.34 60.51 68.04 100.00 92.29 100.00 100.00 96.84 100.00 ∞ ∞ ∞ 
T1 M2 691 + any symptoms 374 0 271 46 39.22 57.98 54.07 61.83 100.00 92.29 100.00 100.00 99.12 100.00 ∞ ∞ ∞ 
T1 M2 691 + malabsorption 255 0 390 46 56.44 39.54 35.74 43.43 100.00 92.29 100.00 100.00 99.02 100.00 ∞ ∞ ∞ 
T2 M1 707 TGA-IgA ≥10xULN 373 0 272 62 38.47 57.83 53.91 61.68 100.00 94.22 100.00 100.00 99.02 100.00 ∞ ∞ ∞ 
T2 M1 707 + any symptoms 340 0 305 62 43.14 52.71 48.78 56.62 100.00 94.22 100.00 100.00 98.92 100.00 ∞ ∞ ∞ 
T2 M1 707 + malabsorption 245 0 400 62 56.58 37.98 34.22 41.86 100.00 94.22 100.00 100.00 98.51 100.00 ∞ ∞ ∞ 
T2 M1 707 TGA-IgA + EMA-IgA 366 0 279 62 39.46 56.74 52.82 60.61 100.00 94.22 100.00 100.00 99.00 100.00 ∞ ∞ ∞ 
T2 M1 707 + any symptoms 334 0 311 62 43.99 51.78 47.85 55.70 100.00 94.22 100.00 100.00 98.90 100.00 ∞ ∞ ∞ 
T2 M1 707 TGA-IgA ≥10xULN 373 0 272 62 38.47 57.83 53.91 61.68 100.00 94.22 100.00 100.00 99.02 100.00 ∞ ∞ ∞ 
T2 M2 691 TGA-IgA ≥10xULN 373 0 272 46 39.36 57.83 53.91 61.68 100.00 92.29 100.00 100.00 99.02 100.00 ∞ ∞ ∞ 
T2 M2 691 + any symptoms 340 0 305 46 44.14 52.71 48.78 56.62 100.00 92.29 100.00 100.00 98.92 100.00 ∞ ∞ ∞ 
T2 M2 691 + malabsorption 245 0 400 46 57.89 37.98 34.22 41.86 100.00 92.29 100.00 100.00 98.51 100.00 ∞ ∞ ∞ 
T2 M2 691 TGA-IgA + EMA-IgA 366 0 279 46 40.38 56.74 52.82 60.61 100.00 92.29 100.00 100.00 99.00 100.00 ∞ ∞ ∞ 
T2 M2 691 + any symptoms 334 0 311 46 45.01 51.78 47.85 55.70 100.00 92.29 100.00 100.00 98.90 100.00 ∞ ∞ ∞ 
T2 M2 691 + malabsorption 240 0 405 46 58.61 37.21 33.47 41.07 100.00 92.29 100.00 100.00 98.48  100.00 ∞ ∞ ∞ 
T3 M1 706 TGA-IgA ≥10xULN 436 0 208 62 29.46 67.70 63.94 71.30 100.00 94.22 100.00 100.00 99.16 100.00 ∞ ∞ ∞ 
T3 M1 706 + any symptoms 393 0 251 62 35.55 61.03 57.14 64.81 100.00 94.22 100.00 100.00 99.07 100.00 ∞ ∞ ∞ 
T3 M1 706 + malabsorption 273 0 371 62 52.55 42.39 38.54 46.31 100.00 94.22 100.00 100.00 98.66 100.00 ∞ ∞ ∞ 
T3 M1 706 TGA-IgA + EMA-IgA 428 0 216 62 30.59 66.46 62.67 70.10 100.00 94.22 100.00 100.00 99.14 100.00 ∞ ∞ ∞ 
T3 M1 706 + any symptoms 386 0 258 62 36.54 59.94 56.04 63.75 100.00 94.22 100.00 100.00 99.05 100.00 ∞ ∞ ∞ 
T3 M1 706 + malabsorption 267 0 377 62 53.40 41.46 37.62 45.37 100.00 94.22 100.00 100.00 98.63 100.00 ∞ ∞ ∞ 
T3 M2 690 TGA-IgA ≥10xULN 436 0 208 46 30.14 67.70 63.94 71.30 100.00 92.29 100.00 100.00 99.16 100.00 ∞ ∞ ∞ 
T3 M2 690 + any symptoms 393 0 251 46 36.38 61.03 57.14 64.81 100.00 92.29 100.00 100.00 99.07 100.00 ∞ ∞ ∞ 
T3 M2 690 + malabsorption 273 0 371 46 53.77 42.39 38.54 46.31 100.00 92.29 100.00 100.00 98.66 100.00 ∞ ∞ ∞ 
T3 M2 690 TGA-IgA + EMA-IgA 428 0 216 46 31.30 66.46 62.67 70.10 100.00 92.29 100.00 100.00 99.14 100.00 ∞ ∞ ∞ 
T3 M2 690 + any symptoms 386 0 258 46 37.39 59.94 56.04 63.75 100.00 92.29 100.00 100.00 99.05 100.00 ∞ ∞ ∞ 
T3 M2 690 + malabsorption 267 0 377 46 54.64 41.46 37.62 45.37 100.00 92.29 100.00 100.00 98.63 100.00 ∞ ∞ ∞ 
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Table S13: Diagnostic accuracies measures and 95% CI for central TGA tests T1 toT9 ≥10xULN ± combinations with EMA and/or symptoms to diagnose CD 
without biopsy , either considering inconclusive cases as no CD (Method M1, N=696-707) or excluding inconclusive cases (M2, N=680-691); 
Test M N Combination  TP FP FN TN False % Sensitivity§ % [95%CI] Specificity % [95%CI] PPV % [95%CI] LR+ [95%CI] 
T4 M1 696 TGA-IgA ≥10xULN 539 1 97 59 14.08 84.75 81.72 87.46 98.333 91.06 99.96 99.82 98.97 100.00 50.85 7.28 355.20 
T4 M1 696 + any symptoms 479 1 157 59 22.70 75.31 71.77 78.62 98.333 91.06 99.96 99.79 98.85 100.00 45.19 6.47 315.70 
T4 M1 696 + malabsorption 325 0 311 60 44.68 51.10 47.14 55.05 100.00 94.04 100.00 100.00 98.87 100.00 ∞ ∞ ∞ 
T4 M1 696 TGA-IgA + EMA-IgA 524 1 112 59 16.24 82.39 79.20 85.27 98.333 91.06 99.96 99.81 98.94 100.00 49.43 7.08 345.30 
T4 M1 696 + any symptoms 466 1 170 59 24.57 73.27 69.65 76.67 98.333 91.06 99.96 99.79 98.81 100.00 43.96 6.29 307.20 
T4 M1 696 + malabsorption 315 0 321 60 46.12 49.53 45.57 53.49 100.00 94.04 100.00 100.00 98.84 100.00 ∞ ∞ ∞ 
T4 M2 680 TGA-IgA ≥10xULN 539 0 97 44 14.26 84.75 81.72 87.46 100.00 91.96 100.00 100.00 99.32 100.00 ∞ ∞ ∞ 
T4 M2 680 + any symptoms 479 0 157 44 23.09 75.31 71.77 78.62 100.00 91.96 100.00 100.00 99.23 100.00 ∞ ∞ ∞ 
T4 M2 680 + malabsorption 325 0 311 44 45.74 51.10 47.14 55.05 100.00 91.96 100.00 100.00 98.87 100.00 ∞ ∞ ∞ 
T4 M2 680 TGA-IgA + EMA-IgA 524 0 112 44 16.47 82.39 79.20 85.27 100.00 91.96 100.00 100.00 99.30 100.00 ∞ ∞ ∞ 
T4 M2 680 + any symptoms 466 0 170 44 25.00 73.27 69.65 76.67 100.00 91.96 100.00 100.00 99.21 100.00 ∞ ∞ ∞ 
T4 M2 680 + malabsorption 315 0 321 44 47.21 49.53 45.57 53.49 100.00 91.96 100.00 100.00 98.84 100.00 ∞ ∞ ∞ 
T5 M1 706 TGA-IgA ≥10xULN 478 0 166 62 23.51 74.22 70.66 77.56 100.00 94.22 100.00 100.00 99.23 100.00 ∞ ∞ ∞ 
T5 M1 706 + any symptoms 431 0 213 62 30.17 66.93 63.14 70.55 100.00 94.22 100.00 100.00 99.15 100.00 ∞ ∞ ∞ 
T5 M1 706 + malabsorption 299 0 345 62 48.87 46.43 42.52 50.37 100.00 94.22 100.00 100.00 98.77 100.00 ∞ ∞ ∞ 
T5 M1 706 TGA-IgA + EMA-IgA 467 0 177 62 25.07 72.52 68.89 75.93 100.00 94.22 100.00 100.00 99.21 100.00 ∞ ∞ ∞ 
T5 M1 706 + any symptoms 422 0 222 62 31.44 65.53 61.72 69.20 100.00 94.22 100.00 100.00 99.13 100.00 ∞ ∞ ∞ 
T5 M1 706 + malabsorption 291 0 353 62 50.00 45.19 41.30 49.12 100.00 94.22 100.00 100.00 98.74 100.00 ∞ ∞ ∞ 
T5 M2 690 TGA-IgA ≥10xULN 478 0 166 46 24.06 74.22 70.66 77.56 100.00 92.29 100.00 100.00 99.23 100.00 ∞ ∞ ∞ 
T5 M2 690 + any symptoms 431 0 213 46 30.87 66.93 63.14 70.55 100.00 92.29 100.00 100.00 99.15 100.00 ∞ ∞ ∞ 
T5 M2 690 + malabsorption 299 0 345 46 50.00 46.43 42.52 50.37 100.00 92.29 100.00 100.00 98.77 100.00 ∞ ∞ ∞ 
T5 M2 690 TGA-IgA + EMA-IgA 467 0 177 46 25.65 72.52 68.89 75.93 100.00 92.29 100.00 100.00 99.21 100.00 ∞ ∞ ∞ 
T5 M2 690 + any symptoms 422 0 222 46 32.17 65.53 61.720 69.20 100.00 92.29 100.00 100.00 99.13 100.00 ∞ ∞ ∞ 
T5 M2 690 + malabsorption 291 0 353 46 51.16 45.19 41.30 49.12 100.00 92.29 100.00 100.00 98.74 100.00 ∞ ∞ ∞ 
T6 M1 707 TGA-IgA ≥10xULN 539 2 106 60 15.28 83.57 80.48 86.34 96.77 88.83 99.61 99.63 98.67 99.96 25.91 6.62 101.30 
T6 M1 707 + any symptoms 478 2 167 60 23.90 74.11 70.55 77.45 96.77 88.83 99.61 99.58 98.50 99.95 22.97 5.87 89.88 
T6 M1 707 + malabsorption 324 0 321 62 45.40 50.23 46.30 54.16 100.00 94.22 100.00 100.00 98.87 100.00 ∞ ∞ ∞ 
T6 M1 707 TGA-IgA + EMA-IgA 523 1 122 61 17.40 81.09 77.85 84.04 98.39 91.34 99.96 99.81 98.94 100.00 50.27 7.19 351.40 
T6 M1 707 + any symptoms 464 1 181 61 25.74 71.94 68.30 75.38 98.39 91.34 99.96 99.79 98.81 100.00 44.60 6.38 311.80 
T6 M1 707 + malabsorption 313 0 332 62 46.96 48.53 44.61 52.46 100.00 94.22 100.00 100.00 98.83 100.00 ∞ ∞ ∞ 
T6 M2 691 TGA-IgA ≥10xULN 539 0 106 46 15.34 83.57 80.48 86.34 100.00 92.29 100.00 100.00 99.32 100.00 ∞ ∞ ∞ 
T6 M2 691 + any symptoms 478 0 167 46 24.17 74.11 70.55 77.45 100.00 92.29 100.00 100.00 99.23 100.00 ∞ ∞ ∞ 
T6 M2 691 + malabsorption 324 0 321 46 46.45 50.23 46.30 54.16 100.00 92.29 100.00 100.00 98.87 100.00 ∞ ∞ ∞ 
T6 M2 691 TGA-IgA + EMA-IgA 523 0 122 46 17.66 81.09 77.85 84.04 100.00 92.29 100.00 100.00 99.30 100.00 ∞ ∞ ∞ 
T6 M2 691 + any symptoms 464 0 181 46 26.19 71.94 68.30 75.38 100.00 92.29 100.00 100.00 99.21 100.00 ∞ ∞ ∞ 
T6 M2 691 + malabsorption 313 0 332 46 48.05 48.53 44.61 52.46 100.00 92.29 100.00 100.00 98.83 100.00 ∞ ∞ ∞ 
§Sensitivity: proportion of patients qualifying for non-biopsy approach;  
*TP=true positive, FP=false positive, FN=false negative, TN=true negative, PPV=positive predictive value, LR+=positive likelihood ratio 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Werkstetter - ProCeDE supplementary manuscript - Submission Gastroenterology 10 Mar 2017  35 
 
Table S13: Diagnostic accuracies measures and 95% CI for central TGA tests T1 toT9 ≥10xULN ± combinations with EMA and/or symptoms to diagnose CD 
without biopsy , either considering inconclusive cases as no CD (Method M1, N=696-707) or excluding inconclusive cases (M2, N=680-691); 
Test M N Combination  TP FP FN TN False % Sensitivity§ % [95%CI] Specificity % [95%CI] PPV % [95%CI] LR+ [95%CI] 
T7 M1 707 TGA-IgA ≥10xULN 446 0 199 62 28.15 69.15 65.42 72.70 100.00 94.22 100.00 100.00 99.18 100.00 ∞ ∞ ∞ 
T7 M1 707 + any symptoms 401 0 244 62 34.51 62.17 58.30 65.93 100.00 94.22 100.00 100.00 99.08 100.00 ∞ ∞ ∞ 
T7 M1 707 + malabsorption 279 0 366 62 51.77 43.26 39.39 47.18 100.00 94.22 100.00 100.00 98.69 100.00 ∞ ∞ ∞ 
T7 M1 707 TGA-IgA + EMA-IgA 437 0 208 62 29.42 67.75 63.99 71.35 100.00 94.22 100.00 100.00 99.16 100.00 ∞ ∞ ∞ 
T7 M1 707 + any symptoms 393 0 252 62 35.64 60.93 57.04 64.72 100.00 94.22 100.00 100.00 99.07 100.00 ∞ ∞ ∞ 
T7 M1 707 + malabsorption 272 0 373 62 52.76 42.17 38.33 46.09 100.00 94.22 100.00 100.00 98.65 100.00 ∞ ∞ ∞ 
T7 M2 691 TGA-IgA ≥10xULN 446 0 199 46 28.80 69.15 65.42 72.70 100.00 92.29 100.00 100.00 99.18 100.00 ∞ ∞ ∞ 
T7 M2 691 + any symptoms 401 0 244 46 35.31 62.17 58.30 65.93 100.00 92.29 100.00 100.00 99.08 100.00 ∞ ∞ ∞ 
T7 M2 691 + malabsorption 279 0 366 46 52.97 43.26 39.39 47.18 100.00 92.29 100.00 100.00 98.69 100.00 ∞ ∞ ∞ 
T7 M2 691 TGA-IgA + EMA-IgA 437 0 208 46 30.10 67.75 63.99 71.35 100.00 92.29 100.00 100.00 99.16 100.00 ∞ ∞ ∞ 
T7 M2 691 + any symptoms 393 0 252 46 36.47 60.93 57.04 64.72 100.00 92.29 100.00 100.00 99.07 100.00 ∞ ∞ ∞ 
T7 M2 691 + malabsorption 272 0 373 46 53.98 42.17 38.33 46.09 100.00 92.29 100.00 100.00 98.65 100.00 ∞ ∞ ∞ 
T8 M1 707 TGA-IgA ≥10xULN 435 0 210 62 29.70 67.44 63.67 71.05 100.00 94.22 100.00 100.00 99.16 100.00 ∞ ∞ ∞ 
T8 M1 707 + any symptoms 391 0 254 62 35.93 60.62 56.73 64.41 100.00 94.22 100.00 100.00 99.06 100.00 ∞ ∞ ∞ 
T8 M1 707 + malabsorption 268 0 377 62 53.32 41.55 37.72 45.46 100.00 94.22 100.00 100.00 98.63 100.00 ∞ ∞ ∞ 
T8 M1 707 TGA-IgA + EMA-IgA 428 0 217 62 30.69 66.36 62.56 70.00 100.00 94.22 100.00 100.00 99.14 100.00 ∞ ∞ ∞ 
T8 M1 707 + any symptoms 384 0 261 62 36.92 59.54 55.63 63.35 100.00 94.22 100.00 100.00 99.04 100.00 ∞ ∞ ∞ 
T8 M1 707 + malabsorption 262 0 383 62 54.17 40.62 36.80 44.52 100.00 94.22 100.00 100.00 98.60 100.00 ∞ ∞ ∞ 
T8 M2 691 TGA-IgA ≥10xULN 435 0 210 46 30.39 67.44 63.67 71.05 100.00 92.29 100.00 100.00 99.16 100.00 ∞ ∞ ∞ 
T8 M2 691 + any symptoms 391 0 254 46 36.76 60.62 56.73 64.41 100.00 92.29 100.00 100.00 99.06 100.00 ∞ ∞ ∞ 
T8 M2 691 + malabsorption 268 0 377 46 54.56 41.55 37.72 45.46 100.00 92.29 100.00 100.00 98.63 100.00 ∞ ∞ ∞ 
T8 M2 691 TGA-IgA + EMA-IgA 428 0 217 46 31.40 66.36 62.56 70.00 100.00 92.29 100.00 100.00 99.14 100.00 ∞ ∞ ∞ 
T8 M2 691 + any symptoms 384 0 261 46 37.77 59.54 55.63 63.35 100.00 92.29 100.00 100.00 99.04 100.00 ∞ ∞ ∞ 
T8 M2 691 + malabsorption 262 0 383 46 55.43 40.62 36.80 44.52 100.00 92.29 100.00 100.00 98.60 100.00 ∞ ∞ ∞ 
T9 M1 707 TGA-IgA ≥10xULN 146 0 499 62 70.58 22.64 19.46 26.06 100.00 94.22 100.00 100.00 97.51 100.00 ∞ ∞ ∞ 
T9 M1 707 + any symptoms 135 0 510 62 72.14 20.93 17.85 24.28 100.00 94.22 100.00 100.00 97.30 100.00 ∞ ∞ ∞ 
T9 M1 707 + malabsorption 99 0 546 62 77.23 15.35 12.65 18.37 100.00 94.22 100.00 100.00 96.34 100.00 ∞ ∞ ∞ 
T9 M1 707 TGA-IgA + EMA-IgA 143 0 502 62 71.00 22.17 19.02 25.58 100.00 94.22 100.00 100.00 97.45 100.00 ∞ ∞ ∞ 
T9 M1 707 + any symptoms 132 0 513 62 72.56 20.47 17.42 23.79 100.00 94.22 100.00 100.00 97.24 100.00 ∞ ∞ ∞ 
T9 M1 707 + malabsorption 96 0 549 62 77.65 14.88 12.23 17.87 100.00 94.22 100.00 100.00 96.23 100.00 ∞ ∞ ∞ 
T9 M2 691 TGA-IgA ≥10xULN 146 0 499 46 72.21 22.64 19.46 26.06 100.00 92.29 100.00 100.00 97.51 100.00 ∞ ∞ ∞ 
T9 M2 691 + any symptoms 135 0 510 46 73.81 20.93 17.85 24.28 100.00 92.29 100.00 100.00 97.30 100.00 ∞ ∞ ∞ 
T9 M2 691 + malabsorption 99 0 546 46 79.02 15.35 12.65 18.37 100.00 92.29 100.00 100.00 96.34 100.00 ∞ ∞ ∞ 
T9 M2 691 TGA-IgA + EMA-IgA 143 0 502 46 72.65 22.17 19.02 25.58 100.00 92.29 100.00 100.00 97.45 100.00 ∞ ∞ ∞ 
T9 M2 691 + any symptoms 132 0 513 46 74.24 20.47 17.42 23.79 100.00 92.29 100.00 100.00 97.24 100.00 ∞ ∞ ∞ 
T9 M2 691 + malabsorption 96 0 549 46 79.45 14.88 12.23 17.87 100.00 92.29 100.00 100.00 96.23 100.00 ∞ ∞ ∞ 
§Sensitivity: proportion of patients qualifying for non-biopsy approach;  
*TP=true positive, FP=false positive, FN=false negative, TN=true negative, PPV=positive predictive value, LR+=positive likelihood ratio 
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Table S14: Diagnostic accuracies measures for central DGP tests 
Table S14: Diagnostic accuracies measures and 95% CI for central DGP tests D1 toT6 ≥10xULN ± combinations with EMA and/or symptoms to diagnose CD 
without biopsy , either considering inconclusive cases as no CD (Method M1, N=678-707) or excluding inconclusive cases (M2, N=678-691); 
Test M N Combination TP FP FN TN False % Sensitivity§ % [95%CI] Specificity % [95%CI] PPV % [95%CI] LR+ [95%CI] 
D1 M1 707 DGP-IgG ≥10xULN 249 1 396 61 56.15 38.61 34.83 42.49 98.39 91.34 99.96 99.60 97.79 99.99 23.93 3.42 167.60 
D1 M1 707 + any symptoms 235 0 410 62 57.99 36.43 32.71 40.28 100.00 94.22 100.00 100.00 98.44 100.00 ∞ ∞ ∞ 
D1 M1 707 + malabsorption 180 0 465 62 65.77 27.91 24.48 31.54 100.00 94.22 100.00 100.00 97.97 100.00 ∞ ∞ ∞ 
D1 M1 707 DGP-IgG + EMA-IgA 245 0 400 62 56.58 37.98 34.22 41.86 100.00 94.22 100.00 100.00 98.51 100.00 ∞ ∞ ∞ 
D1 M1 707 + any symptoms 231 0 414 62 58.56 35.81 32.11 39.65 100.00 94.22 100.00 100.00 98.42 100.00 ∞ ∞ ∞ 
D1 M1 707 + malabsorption 176 0 469 62 66.34 27.29 23.88 30.90 100.00 94.22 100.00 100.00 97.93 100.00 ∞ ∞ ∞ 
D1 M2 691 DGP-IgG ≥10xULN 249 1 396 45 57.45 38.61 34.83 42.49 97.83 88.47 99.95 99.60 97.79 99.99 17.76 2.55 123.70 
D1 M2 691 + any symptoms 235 0 410 46 59.33 36.43 32.71 40.28 100.00 92.29 100.00 100.00 98.44 100.00 ∞ ∞ ∞ 
D1 M2 691 + malabsorption 180 0 465 46 67.29 27.91 24.48 31.54 100.00 92.29 100.00 100.00 97.97 100.00 ∞ ∞ ∞ 
D1 M2 691 DGP-IgG + EMA-IgA 245 0 400 46 57.89 37.98 34.22 41.86 100.00 92.29 100.00 100.00 98.51 100.00 ∞ ∞ ∞ 
D1 M2 691 + any symptoms 231 0 414 46 59.91 35.81 32.11 39.65 100.00 92.29 100.00 100.00 98.42 100.00 ∞ ∞ ∞ 
D1 M2 691 + malabsorption 176 0 469 46 67.87 27.29 23.88 30.90 100.00 92.29 100.00 100.00 97.93 100.00 ∞ ∞ ∞ 
D2 M1 707 DGP-IgG ≥10xULN 16 0 629 62 88.97 2.48 1.42 4.00 100.00 94.22 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M1 707 + any symptoms 16 0 629 62 88.97 2.48 1.42 4.00 100.00 94.22 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M1 707 + malabsorption 16 0 629 62 88.97 2.48 1.42 4.00 100.00 94.22 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M1 707 DGP-IgG + EMA-IgA 16 0 629 62 88.97 2.48 1.42 4.00 100.00 94.22 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M1 707 + any symptoms 16 0 629 62 88.97 2.48 1.42 4.00 100.00 94.22 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M1 707 + malabsorption 16 0 629 62 88.97 2.48 1.42 4.00 100.00 94.22 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M2 691 DGP-IgG ≥10xULN 16 0 629 46 91.03 2.48 1.42 4.00 100.00 92.29 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M2 691 + any symptoms 16 0 629 46 91.03 2.48 1.42 4.00 100.00 92.29 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M2 691 + malabsorption 16 0 629 46 91.03 2.48 1.42 4.00 100.00 92.29 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M2 691 DGP-IgG + EMA-IgA 16 0 629 46 91.03 2.48 1.42 4.00 100.00 92.29 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M2 691 + any symptoms 16 0 629 46 91.03 2.48 1.42 4.00 100.00 92.29 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D2 M2 691 + malabsorption 16 0 629 46 91.03 2.48 1.42 4.00 100.00 92.29 100.00 100.00 79.41 100.00 ∞ ∞ ∞ 
D3 M1 678 DGP-IgG ≥10xULN 302 0 316 60 46.61 48.87 44.86 52.89 100.00 94.04 100.00 100.00 98.79 100.00 ∞ ∞ ∞ 
D3 M1 678 + any symptoms 279 0 339 60 50.00 45.15 41.17 49.17 100.00 94.04 100.00 100.00 98.69 100.00 ∞ ∞ ∞ 
D3 M1 678 + malabsorption 209 0 409 60 60.32 33.82 30.09 37.70 100.00 94.04 100.00 100.00 98.25 100.00 ∞ ∞ ∞ 
D3 M1 678 DGP-IgG + EMA-IgA 297 0 321 60 47.35 48.06 44.06 52.08 100.00 94.04 100.00 100.00 98.77 100.00 ∞ ∞ ∞ 
D3 M1 678 + any symptoms 274 0 344 60 50.74 44.34 40.37 48.35 100.00 94.04 100.00 100.00 98.66 100.00 ∞ ∞ ∞ 
D3 M1 678 + malabsorption 204 0 414 60 61.06 33.01 29.31 36.87 100.00 94.04 100.00 100.00 98.21 100.00 ∞ ∞ ∞ 
D3 M2 662 DGP-IgG ≥10xULN 302 0 316 44 47.73 48.87 44.86 52.89 100.00 91.96 100.00 100.00 98.79 100.00 ∞ ∞ ∞ 
D3 M2 662 + any symptoms 279 0 339 44 51.21 45.15 41.17 49.17 100.00 91.96 100.00 100.00 98.69 100.00 ∞ ∞ ∞ 
D3 M2 662 + malabsorption 209 0 409 44 61.78 33.82 30.09 37.70 100.00 91.96 100.00 100.00 98.25 100.00 ∞ ∞ ∞ 
D3 M2 662 DGP-IgG + EMA-IgA 297 0 321 44 48.49 48.06 44.06 52.08 100.00 91.96 100.00 100.00 98.77 100.00 ∞ ∞ ∞ 
D3 M2 662 + any symptoms 274 0 344 44 51.96 44.34 40.37 48.35 100.00 91.96 100.00 100.00 98.66 100.00 ∞ ∞ ∞ 
D3 M2 662 + malabsorption 204 0 414 44 62.54 33.01 29.31 36.87 100.00 91.96 100.00 100.00 98.21 100.00 ∞ ∞ ∞ 
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Table S14: Diagnostic accuracies measures and 95% CI for central DGP tests D1 toT6 ≥10xULN ± combinations with EMA and/or symptoms to diagnose CD 
without biopsy , either considering inconclusive cases as no CD (Method M1, N=678-707) or excluding inconclusive cases (M2, N=678-691); 
Test M N Combination TP FP FN TN False % Sensitivity§ % [95%CI] Specificity % [95%CI] PPV % [95%CI] LR+ [95%CI] 
D4 M1 706 DGP-IgG ≥10ULN* 275 0 369 62 52.27 42.70 38.85 46.64 100.00 94.22 100.00 100.00 98.67 100.00 ∞ ∞ ∞ 
D4 M1 706 + any symptoms 256 0 388 62 54.96 39.75 35.95 43.65 100.00 94.22 100.00 100.00 98.57 100.00 ∞ ∞ ∞ 
D4 M1 706 + malabsorption 193 0 451 62 63.88 29.97 26.45 33.67 100.00 94.22 100.00 100.00 98.11 100.00 ∞ ∞ ∞ 
D4 M1 706 DGP-IgG + EMA-IgA 270 0 374 62 52.97 41.93 38.08 45.84 100.00 94.22 100.00 100.00 98.64 100.00 ∞ ∞ ∞ 
D4 M1 706 + any symptoms 252 0 392 62 55.52 39.13 35.34 43.02 100.00 94.22 100.00 100.00 98.55 100.00 ∞ ∞ ∞ 
D4 M1 706 + malabsorption 189 0 455 62 64.45 29.35 25.86 33.03 100.00 94.22 100.00 100.00 98.07 100.00 ∞ ∞ ∞ 
D4 M2 690 DGP-IgG ≥10xULN* 275 0 369 46 53.48 42.70 38.85 46.63 100.00 92.29 100.00 100.00 98.67 100.00 ∞ ∞ ∞ 
D4 M2 690 + any symptoms 256 0 388 46 56.23 39.75 35.95 43.65 100.00 92.29 100.00 100.00 98.57 100.00 ∞ ∞ ∞ 
D4 M2 690 + malabsorption 193 0 451 46 65.36 29.97 26.45 33.67 100.00 92.29 100.00 100.00 98.11 100.00 ∞ ∞ ∞ 
D4 M2 690 DGP-IgG + EMA-IgA 270 0 374 46 54.20 41.93 38.08 45.84 100.00 92.29 100.00 100.00 98.64 100.00 ∞ ∞ ∞ 
D4 M2 690 + any symptoms 252 0 392 46 56.81 39.13 35.34 43.02 100.00 92.29 100.00 100.00 98.55 100.00 ∞ ∞ ∞ 
D4 M2 690 + malabsorption 189 0 455 46 65.94 29.35 25.86 33.03 100.00 92.29 100.00 100.00 98.07 100.00 ∞ ∞ ∞ 
D5 M1 707 DGP-IgG ≥8ULN# 152 0 493 62 69.73 23.57 20.34 27.04 100.00 94.22 100.00 100.00 97.60 100.00 ∞ ∞ ∞ 
D5 M1 707 + any symptoms 122 0 523 62 73.97 18.92 15.96 22.15 100.00 94.22 100.00 100.00 97.02 100.00 ∞ ∞ ∞ 
D5 M1 707 + malabsorption 153 0 492 62 69.59 23.72 20.49 27.20 100.00 94.22 100.00 100.00 97.62 100.00 ∞ ∞ ∞ 
D5 M1 707 DGP-IgG + EMA-IgA 153 0 492 62 69.59 23.72 20.49 27.20 100.00 94.22 100.00 100.00 97.62 100.00 ∞ ∞ ∞ 
D5 M1 707 + any symptoms 150 0 495 62 70.01 23.26 20.05 26.71 100.00 94.22 100.00 100.00 97.57 100.00 ∞ ∞ ∞ 
D5 M1 707 + malabsorption 120 0 525 62 74.26 18.61 15.67 21.83 100.00 94.22 100.00 100.00 96.97 100.00 ∞ ∞ ∞ 
D5 M2 691 DGP-IgG ≥8xULN# 155 0 490 46 70.91 24.03 20.78 27.52 100.00 92.29 100.00 100.00 97.65 100.00 ∞ ∞ ∞ 
D5 M2 691 + any symptoms 152 0 493 46 71.35 23.57 20.34 27.04 100.00 92.29 100.00 100.00 97.60 100.00 ∞ ∞ ∞ 
D5 M2 691 + malabsorption 122 0 523 46 75.69 18.92 15.96 22.15 100.00 92.29 100.00 100.00 97.02 100.00 ∞ ∞ ∞ 
D5 M2 691 DGP-IgG + EMA-IgA 153 0 492 46 71.20 23.72 20.49 27.20 100.00 92.29 100.00 100.00 97.62 100.00 ∞ ∞ ∞ 
D5 M2 691 + any symptoms 150 0 495 46 71.64 23.26 20.05 26.71 100.00 92.29 100.00 100.00 97.57 100.00 ∞ ∞ ∞ 
D5 M2 691 + malabsorption 120 0 525 46 75.98 18.61 15.67 21.83 100.00 92.29 100.00 100.00 96.97 100.00 ∞ ∞ ∞ 
D6 M1 707 DGP-IgG ≥10xULN 300 0 345 62 48.80 46.51 42.61 50.45 100.00 94.22 100.00 100.00 98.78 100.00 ∞ ∞ ∞ 
D6 M1 707 + any symptoms 278 0 367 62 51.91 43.10 39.24 47.02 100.00 94.22 100.00 100.00 98.68 100.00 ∞ ∞ ∞ 
D6 M1 707 + malabsorption 208 0 437 62 61.81 32.25 28.65 36.01 100.00 94.22 100.00 100.00 98.24 100.00 ∞ ∞ ∞ 
D6 M1 707 DGP-IgG + EMA-IgA 293 0 352 62 49.79 45.43 41.54 49.36 100.00 94.22 100.00 100.00 98.75 100.00 ∞ ∞ ∞ 
D6 M1 707 + any symptoms 272 0 373 62 52.76 42.17 38.33 46.09 100.00 94.22 100.00 100.00 98.65 100.00 ∞ ∞ ∞ 
D6 M1 707 + malabsorption 202 0 443 62 62.66 31.32 27.75 35.05 100.00 94.22 100.00 100.00 98.19 100.00 ∞ ∞ ∞ 
D6 M2 691 DGP-IgG ≥10xULN 300 0 345 46 69.31 24.03 20.78 27.52 100.00 94.22 100.00 100.00 97.65 100.00 ∞ ∞ ∞ 
D6 M2 691 + any symptoms 278 0 367 46 53.11 43.10 39.24 47.02 100.00 92.29 100.00 100.00 98.68 100.00 ∞ ∞ ∞ 
D6 M2 691 + malabsorption 208 0 437 46 63.24 32.25 28.65 36.01 100.00 92.29 100.00 100.00 98.24 100.00 ∞ ∞ ∞ 
D6 M2 691 DGP-IgG + EMA-IgA 293 0 352 46 50.94 45.43 41.54 49.36 100.00 92.29 100.00 100.00 98.75 100.00 ∞ ∞ ∞ 
D6 M2 691 + any symptoms 272 0 373 46 53.98 42.17 38.33 46.09 100.00 92.29 100.00 100.00 98.65 100.00 ∞ ∞ ∞ 
D6 M2 691 + malabsorption 202 0 443 46 64.11 31.32 27.75 35.05 100.00 92.29 100.00 100.00 98.19 100.00 ∞ ∞ ∞ 
§Sensitivity: proportion of patients qualifying for non-biopsy approach; *TP=true positive, FP=false positive, FN=false negative, TN=true negative, PPV=positive predictive value, LR+=positive likelihood ratio 
# for DGP-IgG test D5, the 10x ULN is 250 U/ml but the maximum measuring range in the central laboratory was 200 U/ml, therefore the 8x ULN was applied 
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Table S15: Agreement between local and central EMA-IgA 
 
Table S15: Agreement in EMA-IgA outcome categorized in negative and positive between the results by the 
laboratory of the clinical study centers and the results from the central study laboratory 
Local  
EMA-IgA 
Central EMA-IgA 
Negative positive Total 
Negative 46 37 83 
Positive 6 589 595 
Total 52 626 678* 
*in 26 patients, local EMA-IgA and in 3 patients central EMA-IgA 
was not available 
 
 
Table S16: Agreement between local and central TGA-IgA 
 
Table S16: Agreement in ≥10xULN TGA-IgA between the local and the corresponding central TGA-IgA of the 
central lab if available and if both serum samples for local and central analyses were taken on the same day 
(N=334). As the real-life situation should be shown, it was not taken into account if the level of normal in the 
local laboratory differed from the manufacturer’s instructions and therefore from the level of normal in the 
central lab.  
Local TGA-IgA  
≥10ULN 
Corresponding central TGA-IgA  
≥10ULN 
No Yes Total 
No 95 18 113 
Yes 25 196 221 
Total 120 214 334 
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Table S17: Agreement between Eu-Gen-risk and EUROArray HLA-typing 
 
Table S17: Agreement between Eu-Gen risk and EUROArray HLA-typing 
Eur-Gen-Risk 
EUROArray HLA-DQ2/DQ8 
Negative Positive DQ2 
Positive 
DQ8 
Positive 
DQ2/DQ8 Total 
Negative 17 0 0 0 17 
Positive DQ2 1** 543 (534)* 1 3 (12)* 548 
Positive DQ8 0 0 49 0 49 
Positive DQ2/DQ8 0 12 (0)* 0 69 (81)* 81 
Total 18 555 50 72 695 
()*if definition of HLA-DQ8 positivity of EUROArray includes not only DQB1*03:02 and DQA1*03:01 but also 
DQB1*03:02 and DQA1*03:02/03 allele as “possible DQ8”: the 12 discrepant cases disappear and are HLA-
DQ2/DQ8 both in EUROArray and in Eu-Gen-Risk; however then 9 additional cases were positive for HLA-
DQ2/DQ8 in EUROArray while Eu-Gen-Risk showed DQ2 only.  
** Both tests detected alleles encoding the β-subunit of DQ2 but not the corresponding α-subunit - interpreted as 
DQ2 positive with Eu-Gen-Risk and as DQ2 negative with EUROArray  
 
Table S18: Agreement between local HLA-typing and EurGen-risk 
 
Table S18: Agreement between local HLA-typing and Eu-Gen-risk 
Eu-Gen-Risk 
Local HLA typing 
Negative Positive DQ2 
Positive 
DQ8 
Positive 
DQ2/DQ8 Total 
Negative 1 0 0 0 1 
Positive DQ2 0 119 2 4 127 
Positive DQ8 0 0 8 0 8 
Positive DQ2/DQ8 0 4 2 11 15 
Total 1 123 12 15 151 
 
Table S19: Agreement between local HLA-typing and EUROArray 
 
Table S19: Agreement between local HLA-typing and EUROArray 
EUROArray HLA-
DQ2/DQ8 
Local HLA typing 
Negative Positive DQ2 
Positive 
DQ8 
Positive 
DQ2/DQ8 Total 
Negative 1 0 0 0 1 
Positive DQ2 0 120 2 5 127 
Positive DQ8 0 0 8 0 8 
Positive DQ2/DQ8 0 3 2 10 15 
Total 1 123 12 15 151 
()*if definition of HLA-DQ8 positivity of EUROArray includes not only DQB1*03:02 and DQA1*03:01 but also 
DQB1*03:02 and DQA1*03:02/03 allele as “possible DQ8”: the 12 discrepant cases disappear and are HLA-
DQ2/DQ8 both in EUROArray and in Eu-Gen-Risk; however then 9 additional cases were positive for HLA-
DQ2/DQ8 in EUROArray while Eu-Gen-Risk showed DQ2 only.  
** Both tests detected alleles encoding the β-subunit of DQ2 but not the corresponding α-subunit - interpreted as 
DQ2 positive with Eu-Gen-Risk and as DQ2 negative with EUROArray 
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Table S20: Agreement between local and central Marsh-Oberhuber staging 
 
Table S20: Agreement between local and central Marsh-Oberhuber staging 
Local 
histopathology 
Marsh-
Oberhuber 
Reference histopathology Marsh-oberhuber staging 
0 1 2 3A 3B 3C Total 
0 25 15 5 7 0 1 53 
1 6 9 4 5 2 2 28 
2 0 3 1 7 5 2 18 
3A 5 3 5 37 22 25 97 
3B 0 6 4 65 61 80 216 
3C 3 2 4 25 81 149 264 
Total 39 38 23 146 171 259 676* 
* in 31 patient the local pathologist did not indicate Marsh staging 
 
 
Table S21: Agreement between local and central histology summary  
 
Table S21: Comparison between local and reference histopathology summarized into indicative for CD (Marsh 
2 to 3A-C) or not (Marsh 0 and 1) 
Local 
histopathology 
indicative for CD? 
Reference histopathology indicative 
for CD?  
No Yes Total 
No 55 26 81 
Yes 22 573 595 
Total 77 599 676* 
* in 31 patients the local pathologist did not indicate Marsh staging 
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Table S22: Agreement between local histology summary and the final central diagnosis 
Table S22: comparison between local histopathology summarized into indicative for CD (Marsh 2 to 3A-C) or 
not (Marsh 0 and 1) and the final central diagnosis 
Local 
histopathology 
indicative for CD? 
Final central diagnosis  
No CD Inconclusive Proven CD Total 
No 32 12 37 81 
Yes 3 3 589 595 
Total 35 15 626 676 
* in 31 patients the local pathologist did not indicate Marsh staging 
 
Table S23: Agreement between local histology statement and the final central diagnosis 
Table S23: Comparison between local histopathology statement (biopsy specimen is considered to show 
normal villi or pathologic signs but not indicative for CD or signs of CD with villous atrophy) and the final 
central diagnosis; in contrast to tables S21 and S22, this table includes  also patients for whom the local 
pathologist did not give any Marsh staging but only the overall summary.  
Local  Final central diagnosis  
histopathology  
statement No CD Inconclusive Proven CD Total 
Normal 32 9 20 61 
Pathologic but no 
CD 11 3 18 32 
Compatible with 
active CD 3 4 607 614 
Total 46 16 645 707 
 
Table S24: Agreement between local and central diagnosis 
Table S24: Comparison between the local diagnosis by the clinical center as reported in the database (no CD, 
unclear, proven CD) and the final central diagnosis (no CD, inconclusive case or proven CD)  
Local diagnosis 
Final central diagnosis  
No CD Inconclusive Proven CD Total 
No CD 31 3 8 42 
Unclear / 
Inconclusive 14 10 37 61 
Proven CD 1 3 600 604 
Total 46 16 645 707 
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